Item 1. Financial Statements and Supplementary Data.

ACREAGE HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

| (in thousands) | Ma | rch 31, 2023 | December 31, 2022 |
|---|----|--------------|--------------------------|
| | (ι | ınaudited) | (audited) |
| ASSETS | | | |
| Cash and cash equivalents | \$ | 14,251 | \$ 24,067 |
| Accounts receivable, net | | 6,546 | 10,512 |
| Inventory | | 53,611 | 49,446 |
| Notes receivable, net | | 1,489 | 29,191 |
| Other current assets | | 4,978 | 4,977 |
| Total current assets | | 80,875 | 118,193 |
| Long-term investments | | 33,293 | 34,046 |
| Capital assets, net | | 135,625 | 133,405 |
| Operating lease right-of-use assets | | 20,842 | 22,443 |
| Intangible assets, net | | 35,124 | 35,124 |
| Goodwill | | 38,694 | 13,761 |
| Other non-current assets | | 3,601 | 3,601 |
| Total non-current assets | | 267,179 | 242,380 |
| TOTAL ASSETS | \$ | 348,054 | \$ 360,573 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | | |
| Accounts payable and accrued liabilities | \$ | 29,077 | \$ 29,566 |
| Taxes payable | | 29,706 | 24,226 |
| Interest payable | | 1,803 | 2,575 |
| Operating lease liability, current | | 2,529 | 2,443 |
| Debt, current | | 1,689 | 1,584 |
| Other current liabilities | | 9,312 | 11,939 |
| Total current liabilities | | 74,116 | 72,333 |
| Debt, non-current | | 215,248 | 213,496 |
| Operating lease liability, non-current | | 20,293 | 21,692 |
| Deferred tax liability | | 10,629 | 9,623 |
| Other liabilities | | 3,129 | 3,250 |
| Total non-current liabilities | | 249,299 | 248,061 |
| TOTAL LIABILITIES | | 323,415 | 320,394 |
| Commitments and contingencies | | | |
| Common stock, no par value - unlimited authorized, 112,724 and 112,437 issued and outstanding, respectively | | _ | _ |
| Additional paid-in capital | | 761,527 | 760,529 |
| Treasury stock, 842 common stock held in treasury | | (21,054) | (21,054) |
| Accumulated deficit | | (693,048) | (678,091) |
| Total Acreage Shareholders' equity | | 47,425 | 61,384 |
| Non-controlling interests | | (22,786) | (21,205) |
| TOTAL EQUITY | | 24,639 | 40,179 |
| TOTAL LIABILITIES AND EQUITY | \$ | 348,054 | \$ 360,573 |

ACREAGE HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

| (in the except of except new shows amounts) | Three Months End | | | |
|---|------------------|----------|----|----------|
| (in thousands, except per share amounts) REVENUE | | 2023 | | 2022 |
| | \$ | 41,881 | \$ | 41 427 |
| Retail revenue, net | Ф | | Э | 41,427 |
| Wholesale revenue, net | | 13,998 | | 15,172 |
| Other revenue, net | | 55.062 | | 280 |
| Total revenues, net | | 55,963 | | 56,879 |
| Cost of goods sold, retail | | (20,414) | | (20,768) |
| Cost of goods sold, wholesale | | (8,964) | | (6,601) |
| Total cost of goods sold | | (29,378) | | (27,369) |
| Gross profit | | 26,585 | | 29,510 |
| OPERATING EXPENSES | | | | |
| General and administrative | | 10,512 | | 8,387 |
| Compensation expense | | 12,203 | | 14,195 |
| Equity-based compensation expense | | 984 | | 4,159 |
| Marketing | | 744 | | 697 |
| Impairments, net | | _ | | 2,138 |
| Write down of assets held-for-sale | | _ | | 874 |
| Legal recoveries | | _ | | (25) |
| Depreciation and amortization | | 997 | | 1,807 |
| Total operating expenses | | 25,440 | | 32,232 |
| Net operating income (loss) | \$ | 1,145 | \$ | (2,722) |
| Income (loss) from investments, net | | (342) | | 1,133 |
| Interest income from loans receivable | | 16 | | 417 |
| Interest expense | | (8,074) | | (4,781) |
| Other loss, net | | (1,553) | | (10) |
| Total other loss | | (9,953) | | (3,241) |
| Loss before income taxes | \$ | (8,808) | \$ | (5,963) |
| Income tax expense | | (7,349) | | (7,948) |
| Net loss | \$ | (16,157) | \$ | (13,911) |
| Lacer not loca ethilostable to non-controlling interests | | (1.5(7) | | (1.217) |
| Less: net loss attributable to non-controlling interests | | (1,567) | | (1,217) |
| Net loss attributable to Acreage Holdings, Inc. | \$ | (14,590) | \$ | (12,694) |
| Net loss per share attributable to Acreage Holdings, Inc basic and diluted: | \$ | (0.13) | \$ | (0.12) |
| Weighted average shares outstanding - basic and diluted | | 112,546 | | 106,900 |

ACREAGE HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY

| (in thousands) | LLC Membership Units | Pubco Shares (as converted) | Share Capital | Treasury Stock | Accumulated Deficit | Shareholders' Equity | Non-controlling Interests | Total Equity |
|---|----------------------------|-----------------------------|---------------|----------------|---------------------|-------------------------|------------------------------|--------------|
| December 31, 2021 | 3,861 | 106,903 | \$ 756,536 | \$ (21,054) | \$ (538,215) | \$ 197,267 | \$ 7,003 | \$ 204,270 |
| NCI adjustments for changes in ownership | _ | _ | 5 | _ | _ | 5 | (5) | _ |
| Equity-based compensation expense and related issuances | _ | 508 | 4,159 | _ | _ | 4,159 | _ | 4,159 |
| Net loss | | | | | (12,694) | (12,694) | (1,217) | (13,911) |
| March 31, 2022 | 3,861 | 107,411 | \$ 760,700 | \$ (21,054) | \$ (550,909) | \$ 188,737 | \$ 5,781 | \$ 194,518 |

| | Attributable to shareholders of the parent | | | | | | | | | |
|--|--|-----------------------------|---------------|-----|-------------|------------------------|-----|-----------------------|------------------------------|--------------|
| (in thousands) | LLC Membership Units | Pubco Shares (as converted) | Share Capital | Tre | asury Stock | Accumulated Deficit | Sha | areholders' Equity | Non-controlling Interests | otal Equity |
| December 31, 2022 | 3,861 | 112,437 | \$ 760,529 | \$ | (21,054) | \$ (678,091) | \$ | 61,384 | \$ (21,205) | \$ 40,179 |
| Cumulative effect of change in accounting principle for current expected credit losses, net of tax | _ | _ | | | _ | (367) | | (367) | _ | (367) |
| NCI adjustments for changes in ownership | _ | _ | 14 | | _ | _ | | 14 | (14) | _ |
| Equity-based compensation expense and related issuances | _ | 287 | 984 | | _ | _ | | 984 | _ | 984 |
| Net loss | _ | _ | _ | | _ | (14,590) | | (14,590) | (1,567) | (16,157) |
| March 31, 2023 | 3,861 | 112,724 | \$ 761,527 | \$ | (21,054) | \$ (693,048) | \$ | 47,425 | \$ (22,786) | \$ 24,639 |

ACREAGE HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

| Three Months E | | | | | | | |
|---|----|----------|----|----------|--|--|--|
| (in thousands) | | 2023 | | 2022 | | | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | | | | | | | |
| Net loss | \$ | (16,157) | \$ | (13,911) | | | |
| Adjustments for: | | | | | | | |
| Depreciation and amortization | | 997 | | 1,807 | | | |
| Depreciation and amortization included in COGS | | 2,287 | | 1,084 | | | |
| Equity-based compensation expense | | 984 | | 4,159 | | | |
| Loss on disposal of capital assets | | _ | | 49 | | | |
| Loss on impairment | | _ | | 2,138 | | | |
| Bad debt expense | | 1,276 | | (96) | | | |
| Non-cash interest expense | | 1,202 | | 644 | | | |
| Non-cash operating lease expense | | (437) | | (9) | | | |
| Deferred tax income | | (9) | | (279) | | | |
| Non-cash (income) loss from investments, net | | 753 | | (788) | | | |
| Write-down of assets held-for-sale | | _ | | 874 | | | |
| Change, net of acquisitions in: | | | | | | | |
| Accounts receivable, net | | 8,102 | | 1,407 | | | |
| Inventory | | (3,535) | | (7,002) | | | |
| Other assets | | 170 | | (1,469) | | | |
| Interest receivable | | (360) | | (417) | | | |
| Accounts payable and accrued liabilities | | (4,184) | | (1,856) | | | |
| Taxes payable | | 4,368 | | 6,071 | | | |
| Interest payable | | (772) | | 1,130 | | | |
| Other liabilities | | (2,755) | | 1,101 | | | |
| Net cash used in operating activities | \$ | (8,070) | \$ | (5,363) | | | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | | | | | | |
| Purchases of capital assets | \$ | (2,230) | \$ | (8,290) | | | |
| Collection of notes receivable | | _ | | 5,279 | | | |
| Business acquisitions, net of cash acquired | | 516 | | _ | | | |
| Distributions from investments | | _ | | 345 | | | |
| Cash paid for short-term investment | | _ | | (3,400) | | | |
| Net cash used in investing activities | \$ | (1,714) | \$ | (6,066) | | | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | | | | | | |
| Deferred financing costs paid | | _ | | (11) | | | |
| Repayment of debt | | (32) | | _ | | | |
| Net cash used in financing activities | \$ | (32) | \$ | (11) | | | |
| Net decrease in cash, cash equivalents, restricted cash, and cash held for sale | \$ | (9,816) | \$ | (11,440) | | | |
| Cash, cash equivalents, restricted cash, and cash held for sale - Beginning of period | | 24,067 | | 44,501 | | | |
| Cash, cash equivalents, restricted cash, and cash held for sale - End of period | \$ | 14,251 | \$ | 33,061 | | | |
| RECONCILIATION OF CASH FLOW INFORMATION: | | | | | | | |
| Cash and cash equivalents | \$ | 14,251 | \$ | 32,619 | | | |
| Restricted cash | | _ | | 95 | | | |

ACREAGE HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

| Cash held for sale | \$ | _ | \$ | 347 |
|--|----|--------------|------|-------------|
| Total cash, cash equivalents, restricted cash, and cash held for sale at end of period | \$ | 14,251 | \$ | 33,061 |
| | Th | ree Months E | Ende | d March 31, |
| (in thousands) | | 2023 | | 2022 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | | | | |
| Interest paid - non-lease | \$ | 7,638 | \$ | 2,446 |
| Income taxes paid | | 2,627 | | 2,065 |
| OTHER NON-CASH INVESTING AND FINANCING ACTIVITIES: | | | | |
| Capital assets not yet paid for | \$ | _ | \$ | 3,631 |
| Non-cash proceeds from finance lease | | _ | | 5,785 |

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

1. NATURE OF OPERATIONS

Acreage Holdings, Inc. (the "Company", "Pubco" or "Acreage") is a vertically integrated, multi-state operator in the United States ("U.S.") cannabis industry and has contractual relationships with cannabis cultivation facilities, dispensaries and other cannabis-related companies in the U.S. The Company's operations include (i) cultivating and processing cannabis plants, (ii) manufacturing branded consumer products, (iii) distributing cannabis flower and manufactured products, and (iv) retailing dosable cannabis products to consumers. The Company's products appeal to medical and adult recreational use customers through brand strategies intended to build trust and loyalty. The Company's Class E subordinate voting shares ("Fixed Shares") and Class D subordinate voting shares ("Floating Shares") are listed on the Canadian Securities Exchange under the symbols "ACRG.A.U" and "ACRG.B.U", respectively, quoted on the OTCQX under the symbols "ACRHF" and "ACRDF", respectively, and traded on the Frankfurt Stock Exchange under the symbols "OVZ1" and "OVZ2", respectively.

High Street Capital Partners, LLC, a Delaware limited liability company doing business as "Acreage Holdings" ("HSCP"), was formed on April 29, 2014. The Company became the indirect parent of HSCP on November 14, 2018 in connection with the reverse takeover ("RTO") transaction described below.

The Company's principal place of business is located at 366 Madison Ave, 14th floor, New York, New York in the U.S. The Company's registered and records office address is Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia in Canada.

The RTO transaction

On September 21, 2018, the Company, HSCP, HSCP Merger Corp. (a wholly-owned subsidiary of the Company), Acreage Finco B.C. Ltd. (a special purpose corporation) ("Finco"), Acreage Holdings America, Inc. ("USCo") and Acreage Holdings WC, Inc. ("USCo2") entered into a business combination agreement (the "Business Combination Agreement") whereby the parties thereto agreed to combine their respective businesses, which would result in the RTO of Pubco by the security holders of HSCP, which was deemed to be the accounting acquiror. On November 14, 2018, the parties to the Business Combination Agreement completed the RTO.

Canopy Growth Corporation transaction

On June 27, 2019, the Company and Canopy Growth Corporation ("Canopy Growth" or "CGC") implemented the Prior Plan of Arrangement (as defined in Note 13) contemplated by the Original Arrangement Agreement (as defined in Note 13). Pursuant to the Prior Plan of Arrangement, Canopy Growth was granted an option to acquire all of the issued and outstanding shares of the Company in exchange for the payment of 0.5818 of a common share in the capital of Canopy Growth for each Class A subordinate voting share (each, a "SVS") held (with the Class B proportionate voting shares (the "PVS") and Class C multiple voting shares (the "MVS") being automatically converted to SVS immediately prior to consummation of the Acquisition (as defined in Note 13), which original exchange ratio was subject to adjustment in accordance with the Original Arrangement Agreement. Canopy Growth was required to exercise the option upon a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijuana (as defined in the relevant legislation) or to remove the regulation of such activities from the federal laws of the United States (the "Triggering Event") and, subject to the satisfaction or waiver of certain closing conditions set out in the Original Arrangement Agreement, Canopy Growth was required to acquire all of the issued and outstanding SVS (following the mandatory conversion of the PVS and MVS into SVS).

On June 24, 2020, Canopy Growth and the Company entered into an agreement to, among other things, amend the terms of the Original Arrangement Agreement and the terms of the Prior Plan of Arrangement (the "Amended Arrangement"). On September 16, 2020, the Company's shareholders voted in favor of a special resolution authorizing and approving the terms of, among other things, the Amended Arrangement. Subsequently, on September 18, 2020, the Company obtained a final order from the Supreme Court of British Columbia approving the Amended Arrangement, and on September 23, 2020 the Company and Canopy Growth entered into the Amending Agreement (as defined in Note 13) and implemented the Amended Arrangement. Pursuant to the Amended Arrangement, the Company's articles were amended to create the Fixed Shares, the Floating Shares and the Class F multiple voting shares (the "Fixed Multiple Shares"), and each outstanding SVS was exchanged for 0.7 of a Fixed Share and 0.3 of a Floating Share, each outstanding PVS was exchanged for 28 Fixed Shares and 12 Floating Shares; and each outstanding MVS was exchanged for 0.7 of a Fixed Multiple Share and 0.3 of a Floating Share. Pursuant to the Amended Arrangement, Canopy Growth was granted the option to acquire all of the issued and outstanding Fixed Shares on the basis of 0.3048 (the "Fixed Exchange Ratio") of a common share of Canopy Growth (each, a "Canopy Share") for each Fixed Share held at the time of the acquisition of the Fixed Shares (the "Acquisition" or "Acquisition Time"), subject to

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

adjustment in accordance with the terms of the Amended Arrangement (the "Canopy Call Option"), which Canopy Growth is required to exercise upon the occurrence, or waiver (at the discretion of Canopy Growth), of a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijuana (as defined in the relevant legislation) or to remove the regulation of such activities from the federal laws of the United States (the "Triggering Event" and the date on which the Triggering Event occurs, the "Triggering Event Date"). Refer to Note 13 for further discussion.

Pursuant to the implementation of the Amended Arrangement, on September 23, 2020, a subsidiary of Canopy Growth advanced gross proceeds of \$50,000 to Universal Hemp, LLC, an affiliate of the Company. The debenture bears interest at a rate of 6.1% per annum. Refer to Note 10 for further discussion.

On October 24, 2022, the Company entered into an arrangement agreement (the "Floating Share Agreement") with Canopy Growth and Canopy USA, LLC ("Canopy USA"), Canopy Growth's newly-created U.S. domiciled holding company, pursuant to which, subject to approval of the holders of the Class D subordinate voting shares of Acreage (the "Floating Shares") and the terms and conditions of the Floating Share Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of court-approved plan of arrangement (the "Floating Share Arrangement") for consideration of 0.4500 of a common share of Canopy Growth (each whole share a "Canopy Share") in exchange for each Floating Share. Refer to Note 13 for further discussion.

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation and going concern

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments consisting only of normal recurring adjustments necessary for a fair presentation have been reflected in these unaudited condensed consolidated financial statements. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any other period.

As reflected in the unaudited condensed consolidated financial statements, the Company had an accumulated deficit as of March 31, 2023, as well as a net loss and negative cash flow from operating activities for the three months ended March 31, 2023. These factors raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the issuance of these financial statements.

However, management believes that substantial doubt about the Company's ability to meet its obligations for the next twelve months from the date these financial statements were issued has been alleviated due to, but not limited to, (i) expected long-term sales growth from the Company's consolidated operations, (ii) latitude as to the timing and amount of certain operating expenses as well as capital expenditures, (iii) expense reduction plans that have already been put in place to improve the Company's results, (iv) the prime rate credit facilities (refer to Notes 10 and 17 for further discussion), (v) proceeds from the sale (with recourse) of certain Employee Retention Tax Credits receivable subsequent to March 31, 2023 and (vi) access to the U.S. and Canadian public equity markets.

If the Company is unable to raise additional capital whenever necessary, it may be forced to decelerate or curtail its footprint build-out or other operational activities until such time as additional capital becomes available. Such limitation of the Company's activities would allow it to slow its rate of spending and extend its use of cash until additional capital is raised. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase the Company's need to raise additional capital on an immediate basis.

These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, dated May 1, 2023, as filed with the Securities and Exchange Commission (the "2022 Form 10-K").

ACREAGE HOLDINGS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except per share data)

Use of estimates

Preparation of financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities as of the dates presented and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates. Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include the fair value of assets acquired and liabilities assumed in business combinations, assumptions relating to equity-based compensation expense, estimated useful lives for property, plant and equipment and intangible assets, the valuation allowance against deferred tax assets and the assessment of potential charges on goodwill, intangible assets and investments in equity and notes receivable.

Emerging growth company

The Company is an "emerging growth company" as defined in the Jumpstart Our Business Startups Act (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.

Functional and presentation currency

The unaudited condensed consolidated financial statements and the accompanying notes are expressed in U.S. dollars. Financial metrics are presented in thousands. Other metrics, such as shares outstanding, are presented in thousands unless otherwise noted.

Basis of consolidation

The Company's unaudited condensed consolidated financial statements include the accounts of Acreage, its subsidiaries and variable interest entities ("VIEs") where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in business entities in which Acreage lacks control but is able to exercise significant influence over operating and financial policies are accounted for using the equity method. The Company's proportionate share of net income or loss of the entity is recorded in *Loss from investments, net* in the Unaudited Condensed Consolidated Statements of Operations.

Non-controlling interests ("NCI")

Non-controlling interests represent ownership interests in consolidated subsidiaries by parties that are not shareholders of Pubco. They are shown as a component of *Total equity* in the Unaudited Condensed Consolidated Statements of Financial Position, and the share of loss attributable to non-controlling interests is shown as a component of *Net loss* in the Unaudited Condensed Consolidated Statements of Operations. Changes in the parent company's ownership that do not result in a loss of control are accounted for as equity transactions.

Cash and cash equivalents

The Company defines cash equivalents as highly liquid investments held for the purpose of meeting short-term cash commitments that are readily convertible into known amounts of cash, with original maturities of three months or less. The Company maintains cash with various U.S. banks and credit unions with balances in excess of the Federal Deposit Insurance Corporation and National Credit Union Share Insurance Fund limits, respectively. The failure of a bank or credit union where the Company has significant deposits could result in a loss of a portion of such cash balances in excess of the insured limit, which could materially and adversely affect the Company's business, financial condition, results of operations and the market price of the Company's Fixed Shares and Floating Shares.

ACREAGE HOLDINGS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except per share data)

Accounts receivable and notes receivable valuations

The Company reports accounts receivable at their net realizable value, which is management's best estimate of the cash that will ultimately be received from customers. The Company's notes receivable represent notes due from various third parties. The Company maintains an allowance for expected credit losses to reflect the expected uncollectability of accounts receivable and notes receivable based on historical collection data and specific risks identified among uncollected accounts, as well as management's expectation of future economic conditions. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the companies receivables and the expected future losses. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Trade accounts receivable and notes receivable are written off after exhaustive collection efforts occur and the receivable is deemed uncollectible. As of March 31, 2023, the allowance for credit losses over accounts receivable and notes receivable and notes

Net loss per share

Net loss per share represents the net loss attributable to shareholders divided by the weighted average number of shares outstanding during the period on an as converted basis. Basic and diluted loss per share are the same as of March 31, 2023, 2022 and 2021, as the issuance of shares upon conversion, exercise or vesting of outstanding units would be anti-dilutive in each period. There were 42,869 and 39,522 anti-dilutive shares outstanding as of March 31, 2023 and 2022, respectively.

Accounting Pronouncements Recently Adopted

As of January 1, 2023, the Company adopted ASU 2016-13 - Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"), which was subsequently revised by ASU 2018-19 and ASU 2020-02. This standard applies to financial assets, measured at amortized cost, including loans, held-to-maturity debt securities, net investments in leases and trade accounts receivable. The guidance must be adopted using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings in the period of adoption. The adoption of ASU 2016-13 did not have a material effect on the Company's unaudited condensed consolidated financial statements.

Accounting Pronouncements Not Yet Adopted

In October 2021, the FASB issued ASU 2021-08 - Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The new standard requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606 - Revenue from Contracts with Customers. The ASU will be effective for the Company's first interim period of fiscal 2024. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company does not anticipate a material impact on the Company's unaudited condensed consolidated financial statements upon adoption.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

3. ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE

Acquisitions

On January 2, 2023, a subsidiary of the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company's operations in Maine. Under the terms of the agreement, the consideration paid consisted of the settlement of a pre-existing relationship, which included a line-of credit, other advances and the related interest receivable, all totaling \$27,691, which were previously recorded in *Notes receivable, net* on the Statements of Financial Position.

The purchase price allocation is based upon preliminary valuations and estimates and assumptions which are subject to change within the measurement period, generally one year from the acquisition date. The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the capital assets, tangible and intangible assets acquired and the residual goodwill resulting from the transaction.

Northoast Dationts

| Purchase Price Allocation | Northeast Patients Group |
|--|--------------------------|
| Assets acquired: | |
| Cash and cash equivalents | \$ 516 |
| Inventory | 384 |
| Other current assets | 5,580 |
| Capital assets | 2,404 |
| Operating lease right-of-use asset | 1,695 |
| Goodwill | 24,933 |
| Liabilities assumed: | |
| Accounts payable and accrued liabilities | (3,679) |
| Taxes payable | (1,112) |
| Operating lease liability, current | (160) |
| Operating lease liability, non-current | (1,844) |
| Notes payable | (11) |
| Deferred tax liability | (1,015) |
| Fair value of net assets acquired | \$ 27,691 |
| | |
| Consideration paid: | |
| Settlement of pre-existing relationship | 27,691 |
| Total consideration | \$ 27,691 |

During the year ended December 31, 2022, the Company did not complete any business acquisitions.

Divestitures

During the three months ended March 31, 2023 and 2022, the Company did not complete any divestitures.

Assets Held for Sale

As of March 31, 2023 and December 31, 2022, the Company did not have any business or assets that met the held-for-sale criteria.

During the three months ended March 31, 2022, the Company recognized a write down of assets held-for-sale of \$874 related to its Oregon operations within Write down (recovery) of assets held-for-sale on the Unaudited Condensed Consolidated Statements of Operations.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

4. INTANGIBLE ASSETS AND GOODWILL

Intangible assets

The following table details the intangible asset balances by major asset classes:

| Intangibles | March 31, 2023 | | December 31, 2022 |
|--|----------------|-----------|-------------------|
| Finite-lived intangible assets: | | | |
| Customer relationships | 1,00 | 00 | 1,000 |
| Total finite-lived intangible assets | 1,00 | 00 | 1,000 |
| Accumulated amortization on finite-lived intangible assets: | | | |
| Customer relationships | (1,00 | 00) | (1,000) |
| Total accumulated amortization on finite-lived intangible assets | (1,00 | 00) | (1,000) |
| Finite-lived intangible assets, net | - | _ | — |
| | | | |
| Indefinite-lived intangible assets | | | |
| Cannabis licenses | 35,12 | 24 | 35,124 |
| Total intangibles, net | \$ 35,12 | <u>\$</u> | 35,124 |

During the year ended December 31, 2022, the Company amended the purchase price allocation related to its acquisition of certain Ohio operations based upon final valuations within the measurement period. As a result, \$17,000 was re-allocated from *Goodwill* to *Intangible assets, net* on the Unaudited Condensed Consolidated Statements of Financial Position.

There was no amortization expense recorded for the three months ended March 31, 2023. Amortization expense associated with the Company's intangible assets was \$696 for the three months ended March 31, 2022.

Goodwill

The following table details the changes in the carrying amount of goodwill:

| Goodwill | Total |
|-------------------|--------------|
| December 31, 2022 | \$ 13,761 |
| Acquisitions | 24,933 |
| March 31, 2023 | \$ 38,694 |

During the three months ended March 31, 2023, the Company recognized \$24,933 of goodwill based on the preliminary purchase price allocation related to the acquisition of Northeast Patients Group. Refer to Note 3 for further discussion.

5. INVESTMENTS

The carrying values of the Company's investments in the Unaudited Condensed Consolidated Statements of Financial Position as of March 31, 2023 and December 31, 2022 are as follows:

| Investments | March 31, 2023 | | | December 31, 2022 |
|-----------------------------|----------------|--------|----|-------------------|
| Investments held at FV-NI | \$ | 33,293 | \$ | 34,046 |
| Total long-term investments | \$ | 33,293 | \$ | 34,046 |

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

Loss from investments, net in the Unaudited Condensed Consolidated Statements of Operations during the three months ended March 31, 2023 and 2022 is as follows:

| Investment income (loss) | T | Three Months Ended March 31, | | | | |
|-------------------------------------|----|------------------------------|-------|--|--|--|
| | | 2023 | 2022 | | | |
| Short-term investments | \$ | 7 \$ | 1 | | | |
| Investments held at FV-NI | | (349) | 1,132 | | | |
| Income (loss) from investments, net | \$ | (342) \$ | 1,133 | | | |

Investments held at FV-NI

The Company has investments in equity of other companies that do not result in significant influence or control. These investments are carried at fair value, with gains and losses recognized in the Unaudited Condensed Consolidated Statements of Operations.

As further described under the "6.10% Secured debenture due September 2030" in Note 10, on September 23, 2020, a subsidiary of the Company, Universal Hemp, LLC ("Universal Hemp") was advanced gross proceeds of \$50,000 (less transaction costs) pursuant to the terms of a secured debenture. The Company subsequently engaged an investment advisor, which under the investment advisor's sole discretion, on September 28, 2020 invested \$34,019 of these proceeds on behalf of Universal Hemp. As a result, Universal Hemp acquired 34,019 class B units, at \$1 par value per unit, which represented 100% financial interest in an Investment Partnership, a Canada-based limited partnership. An affiliate of the institutional investor holds Class A units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The Class B units are held by the Investment Advisor as an agent for Universal Hemp.

Universal Hemp, through its investment with the Investment Advisor, was originally determined to hold significant influence in the Investment Partnership in accordance with ASC 810 due to (1) the economic financial interest, and (2) the entitlement to matters as they pertain to 'Extraordinary Resolution' items as defined within the Investment Partnership Agreement. As a result, the Company accounted for the investment in the Investment Partnership under the equity method until December 2020. Refer to Note 10 for further discussion. In December 2020, the Company no longer held significant influence due to the removal of the Extraordinary Resolution entitlements and other revisions in the Investment Partnership Agreement. As a result, the Company changed its accounting for the Investment Partnership to recognize the investment at fair value, with gains and losses recognized in the Unaudited Condensed Consolidated Statements of Operations.

6. NOTES RECEIVABLE, NET

Notes receivable as of March 31, 2023 and December 31, 2022 consisted of the following:

| | Mar | ch 31, 2023 | De | ecember 31, 2022 |
|---|-----|-------------|----|---------------------|
| Promissory notes receivable | \$ | 9,211 | \$ | 34,088 |
| Line of credit receivable | | 4,331 | | 5,831 |
| Interest receivable | | 3,193 | | 4,147 |
| Allowance for notes and interest receivable | | (15,246) | | (14,875) |
| Total notes receivable | \$ | 1,489 | \$ | 29,191 |
| Less: Notes receivable, current | | 1,489 | | 29,191 |
| Notes receivable, non-current | \$ | | \$ | _ |

Interest income on notes receivable during the three months ended March 31, 2023 and December 31, 2022 was \$16 and \$417, respectively.

At each reporting date, the Company applies its judgment to evaluate the collectability of the note receivable and makes a provision based on the assessed amount of expected credit loss. This judgment is based on parameters such as interest rates, market conditions and creditworthiness of the creditor.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

The Company determined that the collectability of certain notes receivables is doubtful based on information available. As of March 31, 2023 and December 31, 2022, the Company's allowance for notes receivable of \$15,246 and \$14,875, respectively, included \$12,060 and \$12,041 of principal outstanding and \$3,186 and \$2,834 of accrued interest, respectively, and represents the full value of such loan balances.

Activity during the three months ended March 31, 2023

In January 2023, the Company received a \$250 cash payment in full on a promissory note receivable.

In January 2023, a subsidiary of the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company's operations in Maine and the amounts outstanding under the promissory notes receivable were converted into equity in Northeast Patients Group. Refer to Note 3 for further discussion.

Activity during the three months ended March 31, 2022

In February 2022, the Company received a \$5,279 cash payment in full on a line of credit due from Patient Centric Martha's Vineyard, and subsequently closed the line of credit.

7. CAPITAL ASSETS, NET

Net property, plant and equipment consisted of:

| | Mar | ch 31, 2023 | December 31, 2022 | | |
|---|-----|-------------|--------------------------|----------|--|
| Land | \$ | 9,843 | \$ | 9,605 | |
| Building | | 58,366 | | 58,334 | |
| Right-of-use asset, finance leases | | 6,297 | | 5,077 | |
| Furniture, fixtures and equipment | | 40,381 | | 46,811 | |
| Leasehold improvements | | 51,655 | | 6,178 | |
| Construction in progress | | 7,729 | | 34,435 | |
| Capital assets, gross | \$ | 174,271 | \$ | 160,440 | |
| Less: accumulated depreciation and amortization | | (38,646) | | (27,035) | |
| Capital assets, net | \$ | 135,625 | \$ | 133,405 | |

Depreciation and amortization of capital assets for the three months ended March 31, 2023 and 2022 includes \$997 and \$1,111 of depreciation and amortization expense, and \$2,287 and \$1,922 that was capitalized to inventory, respectively.

During the three months ended March 31, 2022, the Company determined that it was unable to find a satisfactory buyer for the held-for-sale assets related to its Michigan operations and, as such, these assets were reclassified as held-and-used. This conclusion was considered a triggering event for capital asset impairment testing. Upon assessment, these specific capital assets were not considered to have future economic value. As such, the fair value of the assets was considered to be nil and the Company recognized an impairment charge of \$1,907 within *Impairments, net* on the Statements of Operations during the three months ended March 31, 2022.

ACREAGE HOLDINGS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except per share data)

8. LEASES

The Company leases land, buildings, equipment and other capital assets which it plans to use for corporate purposes in addition to the production and sale of cannabis products. Leases with an initial term of 12 months or less are not recorded on the Unaudited Condensed Consolidated Statements of Financial Position and are expensed in the Unaudited Condensed Consolidated Statements of Operations on the straight-line basis over the lease term. The Company does not have any material variable lease payments and accounts for non-lease components separately from leases.

| Balance Sheet Information | Classification March 31, 2023 | | December 31, 2022 | | |
|----------------------------------|--|----|-------------------|----|--------|
| Right-of-use assets | | | | | |
| Operating | Operating lease right-of-use assets | \$ | 20,842 | \$ | 22,443 |
| Finance | Capital assets, net | | 4,782 | | 4,269 |
| Total right-of-use assets | | \$ | 25,624 | \$ | 26,712 |
| | | | | | |
| Lease liabilities | | | | | |
| Current | | | | | |
| Operating | Operating lease liability, current | \$ | 2,529 | \$ | 2,443 |
| Financing | Debt, current | | 105 | | 1 |
| Non-current | | | | | |
| Operating | Operating lease liability, non-current | | 20,293 | | 21,692 |
| Financing | Debt, non-current | | 5,877 | | 5,305 |
| Total lease liabilities | | \$ | 28,804 | \$ | 29,441 |

| | | Th | ree Months I | Ended | March 31, |
|--|-------------------------------|----|--------------|-------|-----------|
| Statement of Operations Information | Classification | | 2023 | | 2022 |
| Short-term lease expense | General and administrative | \$ | 151 | \$ | 48 |
| Operating lease expense Finance lease expense: | General and administrative | | 1,337 | | 1,248 |
| Amortization of right of use asset | Depreciation and amortization | | 93 | | 63 |
| Interest expense on lease liabilities | Interest expense | | 209 | | 212 |
| Net operating and finance lease cost | | \$ | 1,639 | \$ | 1,523 |

| | Three Months En | | | | March 31, |
|---|---------------------------------------|----|-------|----|-----------|
| Statement of Cash Flows Information | Classification | | 2023 | | 2022 |
| Cash paid for operating leases | Net cash used in operating activities | \$ | 1,774 | \$ | 1,257 |
| Cash paid for finance leases - interest | Net cash used in operating activities | \$ | 269 | \$ | 201 |

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

The following represents the Company's future minimum payments required under existing leases with initial terms of one year or more as of March 31, 2023:

| Maturity of lease liabilities | Opera | ting Leases | Finance Leases | |
|---|-------|-------------|----------------|--------|
| 2023 | \$ | 3,359 | \$ | 677 |
| 2024 | | 4,522 | | 923 |
| 2025 | | 4,485 | | 946 |
| 2026 | | 4,551 | | 969 |
| 2027 | | 4,037 | | 992 |
| Thereafter | | 13,267 | | 11,705 |
| Total lease payments | \$ | 34,221 | \$ | 16,212 |
| Less: interest | | 11,399 | | 10,230 |
| Present value of lease liabilities | \$ | 22,822 | \$ | 5,982 |
| Weighted average remaining lease term (years) | | 8 | | 12 |
| Weighted average discount rate | | 10% | | 12% |

As of March 31, 2023, there have been no leases entered into that have not yet commenced.

9. INVENTORY

The Company's inventory balance consists of the following:

| | Marc | h 31, 2023 | December 31, 2022 | | |
|-----------------------|------|------------|--------------------------|--------|--|
| Retail inventory | \$ | 3,723 | \$ | 3,255 | |
| Wholesale inventory | | 40,832 | | 35,885 | |
| Cultivation inventory | | 6,469 | | 7,133 | |
| Supplies & other | | 2,587 | | 3,173 | |
| Total | \$ | 53,611 | \$ | 49,446 | |

Inventory is valued at the lower of cost and net realizable value ("NRV"), defined as estimated selling price in the ordinary course of business, less estimated costs of disposal. During the three months ended March 31, 2023, the Company analyzed its inventory balances, and recorded wholesale inventory adjustments as a result of (i) having excess or obsolete inventory and (ii) reducing the carrying value to ensure inventory balances are properly recorded at the lower of cost and NRV. The Company recognized \$2,237 of wholesale inventory adjustments within *Cost of goods sold, wholesale* on the Statements of Operations during the three months ended March 31, 2023.

10. DEBT

The Company's debt balances consist of the following:

| Debt balances | Mar | March 31, 2023 | | ber 31, 2022 |
|---|-----|----------------|----|--------------|
| Financing liability (failed sale-leaseback) | \$ | 15,253 | \$ | 15,253 |
| Finance lease liabilities | | 5,982 | | 5,306 |
| 7.50% Loan due April 2026 | | 31,418 | | 31,288 |
| 6.10% Secured debenture due September 2030 | | 46,614 | | 46,502 |
| Note due December 2024 | | 3,167 | | 3,167 |
| Prime rate credit facilities due January 2026, as amended | | 114,503 | | 113,564 |
| Total debt | \$ | 216,937 | \$ | 215,080 |
| Less: current portion of debt | | 1,689 | | 1,584 |
| Total long-term debt | \$ | 215,248 | \$ | 213,496 |

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

Scheduled maturities of debt, excluding amortization of discount and issuance costs, are as follows:

| 2023 | \$ 1,583 |
|--|---------------|
| 2024 | 1,584 |
| 2025 | _ |
| 2026 | 158,011 |
| 2027 | 39 |
| Thereafter | 71,185 |
| Total payments (excluding amortization of discount and issuance costs) | \$ 232,402 |

During the three months ended March 31, 2023 and 2022, the Company incurred interest expense of \$8,074 and \$4,781, respectively, on the Unaudited Condensed Consolidated Statements of Operations. Interest expense for the three months ended March 31, 2023 and 2022, included debt discount amortization of \$488 and \$373, respectively, and amortization of debt issuance costs of \$690 and \$266, respectively. As of March 31, 2023 and December 31, 2022, the Company had unamortized discount \$5,603 and \$6,093, respectively, and debt issuance costs of \$9,862 and \$10,552, respectively, which is netted against the gross carrying value of long-term debt in *Debt, non-current* on Unaudited Condensed Consolidated Statements of Financial Position. Additionally, as of March 31, 2023 and December 31, 2022, the Company had accrued interest of \$1,803 and \$2,575, respectively, within *Interest payable* on the Unaudited Condensed Consolidated Statements of Financial Position.

Financing liability (failed sales leaseback)

In connection with the Company's failed sale-leaseback transaction in November 2020, a financing liability was recognized equal to the cash proceeds received. The Company will recognize the cash payments made on the lease as interest expense, and the principal will be de-recognized upon expiration of the lease.

6.10% Secured debenture due September 2030

On September 23, 2020, pursuant to the implementation of the Amended Arrangement (Refer to Note 13 for further discussion), a subsidiary of Canopy Growth advanced gross proceeds of \$50,000 (less transaction costs of approximately \$4,025) to Universal Hemp, an affiliate of the Company, pursuant to the terms of a secured debenture ("6.1% Loan"). In accordance with the terms of the debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. An additional \$50,000 may be advanced pursuant to the debenture subject to the satisfaction of certain conditions by Universal Hemp. The debenture bears interest at a rate of 6.1% per annum, matures 10 years from the date hereof or such earlier date in accordance with the terms of the debenture and all interest payments made pursuant to the debenture are payable in cash by Universal Hemp. The debenture is secured by substantially all of the assets of Universal Hemp and its subsidiaries and, further, is not convertible and is not guaranteed by Acreage.

With a portion of the proceeds for the 6.1% Loan received by Universal Hemp, Acreage engaged an Investment Advisor which, under the Investment Advisor's sole discretion, invested on behalf of Universal Hemp \$34,019 on September 28, 2020. As a result, Universal Hemp acquired 34,019 class B units, at \$1.00 par value per unit, which represented 100% financial interest in the Investment Partnership, a Canada-based limited partnership. An affiliate of the Institutional Investor holds class A units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The class B units are held by the Investment Advisor as an agent for Universal Hemp. Upon execution of the limited partnership agreement, \$1,019 was distributed to the class A unit holders of the Investment Partnership.

7.50% Loan due April 2026

On September 28, 2020, the Company received gross proceeds of \$33,000 (less transaction costs of approximately \$959) from an affiliate of the Institutional Investor (the "Lender") and used a portion of the proceeds of this loan to retire its short-term \$11,000 convertible note (as described above) and its short-term note aggregating approximately \$18,000 in October 2020, with the remainder being used for working capital purposes. The loan is unsecured, matures in 3 years and bears interest at a 7.5% annual interest rate. The Lender is controlled by the Institutional Investor. The Investment Partnership is the investor in the Lender. On December 16, 2021, the Company paid an amendment fee of \$413 to extend the maturity date from September 28, 2023 to April 2, 2026. The amendment was treated as a debt extinguishment.

Note due December 2024

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

In November 2020, the Company issued a promissory note with a third party, which is non-interest bearing and payable based on a payment schedule with ten payments in the aggregate amount of \$7,750 through December 31, 2024, as a result of a settlement described under the "CanWell Dispute" in Note 13.

Prime rate credit facilities due January 2026, as amended

On December 16, 2021, the Company entered into a \$150,000 senior secured credit facility with a syndicate of lenders consisting of a \$75,000 initial draw, a \$25,000 delayed draw that must be advanced within 12 months and a \$50,000 committed accordion facility that is available after December 1, 2022, provided certain financial covenants are met, and with a maturity of January 1, 2026. Upon closing, gross proceeds of \$75,000 were drawn (before origination discounts and issuance costs of approximately \$4,000 and \$1,500, respectively, which were capitalized). In April 2022, the Company drew down on the \$25,000 delayed draw. Refer to Note 14 for further discussion of the syndicated related party lender.

On October 24, 2022, the Company amended the senior secured credit facility such that \$25,000 of the committed accordion was available for immediate draw by Acreage, which was drawn down in the fourth quarter of 2022, with the remaining \$25,000 available from January 1, 2023, provided certain predetermined milestones are achieved. The Company paid an amendment fee of \$1,250 to the syndicate of lenders and the amendment was treated as a debt modification.

On April 28, 2023, the Company reached an agreement with the lenders of the Prime rate credit facilities due January 2026 that would allow it to draw a further \$15,000 under its current Credit Agreement, but such funds would be maintained in a segregated account until dispersed and be restricted for use to only eligible capital expenditures. As part of this agreement, the Company agreed to limit the total amounts outstanding under the Credit Agreement to \$140,000 and to at all times subsequent to the amendment, maintain collateral (as defined in the Credit Agreement) equal to or greater than the outstanding amount under the Credit Agreement.

The loan is secured by pledged equity interests and substantially all of the assets of the Company. Advances under the facility bear interest at a variable rate of U.S. prime ("Prime") plus 5.75% per annum, payable monthly in arrears, with a Prime floor of 5.50% plus an additional 1.0% per annum until certain collateral assignment agreements are delivered. Undrawn amounts bear interest at 3.0% per annum.

The facility has a maturity date of January 1, 2026 and the Company has the option to extend the maturity date to January 1, 2027, for a fee equal to 1.0% of the total loan amount.

The loan is subject to various financial covenants, including (i) a fixed charge coverage ratio and two leverage ratios in respect of all periods beginning on or after December 31, 2023 and (ii) a minimum cash requirement of \$10.0 million at each quarter end of the Company. Finally, the Amended Credit Facility includes approval for Canopy USA to acquire control of Acreage without requiring repayment of all amounts outstanding under the Amended Credit Facility, provided certain conditions are satisfied. As of March 31, 2023 the Company was in compliance with all covenants.

The Company obtained a waiver of the financial covenants for the three month periods ended March 31, 2022 and June 30, 2022. This waiver included a \$500 waiver fee that was paid to the lenders.

11. SHAREHOLDERS' EQUITY AND NON-CONTROLLING INTERESTS

The table below details the change in Pubco shares outstanding by class for the three months ended March 31, 2023:

| Shareholders' Equity | Fixed Shares | Floating Shares | Fixed Shares Held in Treasury | Floating Shares Held in Treasury | Fixed Multiple Shares | Total Shares Outstanding |
|--------------------------|--------------|--------------------|-------------------------------------|--|-----------------------------|-----------------------------|
| December 31, 2022 | 79,047 | 34,114 | (589) | (253) | 118 | 112,437 |
| Issuances | 209 | 78 | | | | 287 |
| NCI conversions | <u>—</u> | <u>—</u> | <u>—</u> | <u> </u> | <u> </u> | _ |
| March 31, 2023 | 79,256 | 34,192 | (589) | (253) | 118 | 112,724 |

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

Warrants

A summary of the warrants activity outstanding is as follows:

| Warrants | Fixed Shares | Floating Shares |
|-------------------|--------------|-----------------|
| December 31, 2022 | 5,817 | 2,524 |
| Expired | | |
| March 31, 2023 | 5,817 | 2,524 |

The exercise price of each Fixed Share warrant ranged from \$3.15 to \$4.00, respectively, and the exercise price of each Floating Share warrant ranged from \$3.01 to \$4.00, respectively. The warrants are exercisable for a period of 4 years. The weighted-average remaining contractual life of the warrants outstanding is approximately 1.7 years. There was no aggregate intrinsic value for warrants outstanding as of March 31, 2023.

Non-controlling interests - convertible units

The Company has NCIs in consolidated subsidiaries USCo2 and HSCP. The non-voting shares of USCo2 and HSCP units make up substantially all of the NCI balance as of March 31, 2023 and are convertible for either 0.7 of a Fixed Share and 0.3 of a Floating Share of Pubco or cash, as determined by the Company. Summarized financial information of HSCP is presented below. USCo2 does not have discrete financial information separate from HSCP.

| HSCP net asset reconciliation | March 31, 2023 | December 31, 2022 | | |
|---------------------------------------|--------------------|-------------------|-----------|--|
| Current assets | \$ 80,875 | \$ | 118,193 | |
| Non-current assets | 262,465 | | 237,665 | |
| Current liabilities | (4,357) | | (9,141) | |
| Non-current liabilities | (240,776) | | (239,525) | |
| Other NCI balances | (729) | | (725) | |
| Accumulated equity-settled expenses | (241,744) | | (240,760) | |
| Net assets | \$ (144,266) | \$ | (134,293) | |
| HSCP/USCo2 ownership % of HSCP | 16.30 % | | 16.33 % | |
| Net assets allocated to USCo2/HSCP | \$ (23,515) | \$ | (21,930) | |
| Net assets attributable to other NCIs | 729 | | 725 | |
| Total NCI | \$ (22,786) | \$ | (21,205) | |

| | Three Months Ended M | | | | |
|---|----------------------|---------|----|---------|--|
| HSCP Summarized Statement of Operations | 2023 | | | 2022 | |
| Net loss allocable to HSCP/USCo2 | \$ | (9,601) | \$ | (7,080) | |
| HSCP/USCo2 weighted average ownership % of HSCP | | 16.31 % | | 17.21 % | |
| Net loss allocated to HSCP/USCo2 | \$ | (1,566) | \$ | (1,218) | |
| Net loss allocated to other NCIs | | (1) | | 1 | |
| Net loss attributable to NCIs | \$ | (1,567) | \$ | (1,217) | |

As of March 31, 2023, USCo2's non-voting shares owned approximately 0.22% of HSCP units. USCo2's capital structure is comprised of voting shares, all of which are held by the Company, and of non-voting shares held by certain former HSCP members. Certain executive employees and profits interests holders own approximately 16.08% of HSCP units. The remaining 83.70% interest in HSCP is held by USCo and represents the members' equity attributable to shareholders of the parent.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

A reconciliation of the beginning and ending amounts of convertible units is as follows:

| Convertible Units | March 31, 2023 | December 31, 2022 |
|------------------------------|----------------|--------------------------|
| Beginning balance | 22,698 | 23,076 |
| NCI units converted to Pubco | - | (378) |
| Ending balance | 22,698 | 22,698 |

12. EQUITY-BASED COMPENSATION EXPENSE

Amended Arrangement with Canopy Growth

On September 23, 2020, the Company announced the implementation of the Amended Arrangement (as defined in Note 13). Pursuant to the Amended Arrangement, the Company's articles have been amended to create new Fixed Shares, Floating Shares and Fixed Multiple Shares. Consequently, the Company's equity-based compensation was modified into new equity awards of the Company. Refer to Note 13 for further discussion.

Equity-based compensation - Plan (Acreage Holdings, Inc. Omnibus Incentive Plan)

In connection with the RTO transaction, the Company's Board of Directors adopted an Omnibus Incentive Plan, as amended September 23, 2020 (the "Plan"), which permits the issuance of stock options, stock appreciation rights, stock awards, share units, performance shares, performance units and other stock-based awards up to an amount equal to 15% of the issued and outstanding Subordinate Voting Shares of the Company.

Pursuant to the Amended Arrangement, the Company retained the Plan described above, the upper limit of issuances being up to an amount equal to 15% of the issued and outstanding Fixed Shares and Floating Shares of the Company. As of March 31, 2023, the Company had 4,212 shares authorized and available for grant under the Plan.

Restricted Share Units ("RSUs")

| | Fixed S | Shar | es | Floating Shares | | | |
|---|---------|------|---|-----------------|----|--|--|
| Restricted Share Units (Fair value information expressed in whole dollars) | RSUs | Av | Weighted erage Grant e Fair Value | RSUs | Av | Weighted erage Grant te Fair Value | |
| Unvested, January 1, 2023 | 6,324 | \$ | 1.80 | 464 | \$ | 6.68 | |
| Granted | | \$ | | _ | \$ | | |
| Forfeited | (109) | \$ | 0.98 | (1) | \$ | 2.15 | |
| Vested | (458) | \$ | 2.17 | (161) | \$ | 2.24 | |
| Unvested, March 31, 2023 | 5,757 | \$ | 1.79 | 302 | \$ | 9.06 | |
| Vested and unreleased ⁽¹⁾ | 449 | \$ | 2.50 | 147 | \$ | 3.16 | |
| Outstanding, March 31, 2023 | 6,206 | \$ | 1.84 | 449 | \$ | 7.13 | |

⁽¹⁾ RSUs that are vested and unreleased represent RSUs that are pending delivery.

RSUs of the Company generally vest over a period of three years and RSUs granted to certain executives vest based on achievement of specific performance conditions. In certain situations for specified individuals, RSUs vest on an accelerated basis on separation. The fair value for RSUs is based on the Company's share price on the date of the grant. The Company recorded \$758 and \$3,877 as *Equity-based compensation expense* relating to RSUs on the Unaudited Condensed Consolidated Statements of Operations during the three months ended March 31, 2023 and 2022, respectively. The fair value of RSUs vested during the three months ended March 31, 2023 and 2022 was \$442 and \$1,882, respectively.

The total weighted average remaining contractual life and aggregate intrinsic value of unvested RSUs as of March 31, 2023 was approximately 2.0 years and \$3,214, respectively. Unrecognized compensation expense related to these awards at March 31, 2023 was \$11,054 and is expected to be recognized over a weighted average period of approximately 1.7 years.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

Stock options

| | Fixed | Shar | es | Floating Shares | | | |
|---|---|------|------|-----------------|----|------|--|
| Stock Options (Exercise price expressed in whole dollars) | Weighted Average pressed in whole dollars) Options Exercise Price | | | | | | |
| Options outstanding, January 1, 2023 | 7,337 | \$ | 2.75 | 2,267 | \$ | 3.10 | |
| Granted | <u> </u> | \$ | _ | _ | \$ | _ | |
| Forfeited | _ | \$ | _ | _ | \$ | _ | |
| Expired | <u> </u> | \$ | _ | (31) | \$ | 2.55 | |
| Options outstanding, March 31, 2023 | 7,337 | \$ | 2.75 | 2,236 | \$ | 3.10 | |
| | | | - | | | | |
| Options exercisable, March 31, 2023 | 1,834 | \$ | 9.14 | 2,106 | \$ | 3.10 | |

Stock options of the Company generally vest over a period of three years and options granted to certain executives vest based on achievement of specific performance conditions. Stock options of the Company have an expiration period of 5 or 10 years from the date of grant. The weighted average contractual life remaining for Fixed Share options outstanding and exercisable as of March 31, 2023 was approximately 5 and 6 years, respectively. The weighted average contractual life remaining for Floating Share options outstanding and exercisable as of March 31, 2023 was approximately 6 and 7 years, respectively. The Company recorded \$226 and \$282 as *Equity-based compensation expense* on Unaudited Condensed Consolidated Statements of Operations during the three months ended March 31, 2023 and 2022, respectively.

As of March 31, 2023, unamortized expense related to stock options totaled \$1,670 and is expected to be recognized over a weighted-average period of approximately 2 years. As of March 31, 2023, the aggregate intrinsic value for unvested options and for vested and exercisable options was nil, respectively.

13. COMMITMENTS AND CONTINGENCIES

Commitments

The Company provides revolving lines of credit to certain of its portfolio companies. As of March 31, 2023, only one revolving line of credit remained outstanding and the maximum obligation under this arrangement was equal to the balance advanced of \$4,331 (refer to Note 6 for further discussion).

Prior Plan of Arrangement with Canopy Growth

On June 19, 2019, the shareholders of the Company and of Canopy Growth separately approved the proposed plan of arrangement (the "Prior Plan of Arrangement") involving the two companies, and on June 21, 2019, the Supreme Court of British Columbia granted a final order approving the Prior Plan of Arrangement. Effective June 27, 2019, the articles of the Company were amended pursuant to the Prior Plan of Arrangement to provide that, upon the occurrence (or waiver by Canopy Growth) of the Triggering Event, subject to the satisfaction of the conditions set out in the arrangement agreement entered into between Acreage and Canopy Growth on April 18, 2019, as amended on May 15, 2019 (the "Original Arrangement Agreement"), Canopy Growth will acquire (the "Acquisition") all of the issued and outstanding shares in the capital of the Company (each, an "Acreage Share").

Second Amendment to the Arrangement Agreement with Canopy Growth

On September 23, 2020, Acreage and Canopy Growth entered into an amending agreement (the "Amending Agreement" or "Amended Arrangement") (and together with the Original Arrangement Agreement and any further amendments thereto, the "Amended Plan of Arrangement") and the Amended Arrangement became effective at 12:01 a.m. (Vancouver time) (the "Amendment Time") on September 23, 2020 (the "Amendment Date"). Pursuant to the Amended Plan of Arrangement, Canopy Growth made a cash payment of \$37,500 which was delivered to Acreage's shareholders and certain holders of securities convertible or exchangeable into shares of Acreage. Acreage also completed a capital reorganization (the "Capital Reorganization") effective as of the Amendment Time whereby: (i) each existing SVS was exchanged for 0.7 of a Fixed Share and 0.3 of a Floating Share; (ii) each issued and outstanding PVS was exchanged for 28 Fixed Shares and 12 Floating Shares; and (iii) each issued and outstanding MVS was exchanged for 0.7 of a Fixed Multiple Share and 0.3 of a Floating Share.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

At the Amendment Time, each option, restricted share unit, compensation option, and warrant to acquire existing SVS (each a "Security") that was outstanding immediately prior to the Amendment Time, was exchanged for a replacement Security to acquire Fixed Shares (a "Fixed Share Replacement Security") and a replacement Security to acquire Floating Shares (a "Floating Share Replacement Security") to account for the Capital Reorganization.

Pursuant to the Amended Plan of Arrangement, upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event (the "Triggering Event Date"), Canopy Growth will, subject to the satisfaction or waiver of certain closing conditions set out in the Arrangement Agreement: (i) acquire all of the issued and outstanding Fixed Shares (following the mandatory conversion of the Fixed Multiple Shares into Fixed Shares) on the basis of 0.3048 of a common share of Canopy Growth (each whole common share, a "Canopy Growth Share") for each Fixed Share held (the "Fixed Exchange Ratio") at the time of the acquisition of the Fixed Shares (the "Acquisition Time"), subject to adjustment in accordance with the terms of the Amended Plan of Arrangement (the "Canopy Call Option"). The Canopy Call Option and the Floating Call Option will expire 10 years from the Amendment Time.

At the Acquisition Time, on the terms and subject to the conditions of the Amended Plan of Arrangement, each Fixed Share Replacement Security will be exchanged for a replacement Security from Canopy Growth equal to: (i) the number of Fixed Shares that were issuable upon exercise of such Fixed Share Replacement Security immediately prior to the Acquisition Time, multiplied by (ii) the Fixed Exchange Ratio in effect immediately prior to the Acquisition Time (provided that if the foregoing would result in the issuance of a fraction of a Canopy Growth Share, then the number of Canopy Growth Shares to be issued will be rounded down to the nearest whole number).

The Amended Plan of Arrangement provides for, among other things, Amendments to the definition of Purchaser Approved Share Threshold (as defined therein) to change the number of shares of Acreage available to be issued by Acreage without an adjustment in the Fixed Exchange Ratio such that Acreage may issue a maximum of 32,700 shares. Furthermore, Acreage generally may not issue any equity securities without Canopy Growth's prior consent. Additionally, the Amended Plan of Arrangement allows for various Canopy Growth rights that extend beyond the Acquisition Date, including, among others: (i) rights to nominate a majority of Acreage's Board of Directors following the Acquisition Time; (ii) restrictive covenants in respect of the business conduct in favor of Canopy Growth; (iii) termination of non-competition and exclusivity rights granted to Acreage by Canopy Growth in the event that Acreage does not meet certain specified financial targets; (iv) implementation of further restrictions on Acreage's ability to operate its business in the event that Acreage does not meet certain specified financial targets; and (v) termination of the Amended Plan of Arrangement in the event that Acreage does not meet certain specified financial targets in the trailing 12 month period. Each of the financial targets referred to above is specified in the Amending Agreement and related to the performance of Acreage relative to a business plan for Acreage for each fiscal year ended December 31, 2020 through December 31, 2029 set forth in the Proposal Agreement (the "Initial Business Plan").

Further, the Amended Plan of Arrangement imposes restrictions on Acreage entering into any contracts in respect of Company Debt if: (i) such contract would be materially inconsistent with market standards for companies operating in the United States cannabis industry; (ii) such contract prohibits a prepayment of the principal amount of such Company Debt; and (iii) such contract would provide for interest payments to be paid through the issuance of securities as opposed to cash, among other restrictions. The Amended Plan of Arrangement also provides for the following: (i) certain financial reporting obligations to Canopy Growth; (ii) certain specified criteria related to any new directors or officers of Acreage, and (iii) a limit to Acreage's operations to the Identified States (as defined therein).

Third Amendment to the Arrangement Agreement with Canopy Growth

On October 24, 2022, the Company entered into an arrangement agreement (the "Floating Share Agreement") with Canopy Growth and Canopy USA, LLC ("Canopy USA"), Canopy Growth's newly-created U.S. domiciled holding company, pursuant to which, subject to approval of the holders of the Class D subordinate voting shares of Acreage (the "Floating Shares") and the terms and conditions of the Floating Share Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of court-approved plan of arrangement (the "Floating Share Arrangement") for consideration of 0.4500 of a common share of Canopy Growth (each whole share a "Canopy Share") in exchange for each Floating Share. A special meeting of the holders of Floating Shares was held on March 15, 2023, where the holders of Floating Shares approved the Floating Share Arrangement (the "Special Meeting").

Concurrently with entering the Floating Share Agreement, Canopy Growth irrevocably waived its option to acquire the Floating Shares pursuant to the Amended Arrangement.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

Subject to the provisions of the Floating Share Agreement, Canopy Growth has agreed to exercise the fixed option pursuant to the Amended Agreement to acquire all outstanding Fixed Shares, representing approximately 70% of the total shares of Acreage as at the date hereof, at a fixed exchange ratio of 0.3048 of a Canopy Share for each Fixed Share.

Acreage expects the Floating Share Arrangement to close upon the satisfaction or waiver of all conditions under the Floating Share Agreement and the Amended Arrangement. It is anticipated that the acquisition by Canopy USA of the Fixed Shares pursuant to the Fixed Option will be completed immediately following closing of the Floating Share Agreement. In the event that Canopy USA exercises the Fixed Option and acquires the Floating Shares pursuant to the Floating Share Arrangement, Acreage will be wholly-owned subsidiary of Canopy USA.

On March 17, 2023, Acreage, Canopy and Canopy USA entered into a first amendment to the Floating Share Arrangement Agreement (the "Amendment"). Pursuant to the terms of the Amendment, Acreage, Canopy and Canopy USA agreed to amend the Exercise Outside Date (as defined in the Floating Share Arrangement Agreement) from March 31, 2023 to May 31, 2023.

Tax Receivable Agreement and Tax Receivable Bonus Plans

The Company is a party to (i) a tax receivable agreement dated November 14, 2018 and subsequently amended (the "Tax Receivable Agreement") between the Company and certain current and former unit holders of HSCP and (ii) tax receivable bonus plans dated November 14, 2018 and subsequently amended (the "Tax Receivable Bonus Plans") between the Company and certain directors, officers and consultants of the Company (together the "Tax Receivable Recipients"). Under the Tax Receivable Agreement and the Tax Receivable Bonus Plans, the Company is required to make cash payments to the Tax Receivable Recipients equal to 85% of the tax benefits, if any, that the Company actually realizes, or in certain circumstances is deemed to realize, as a result of (i) the increases in its share of the tax basis of assets of HSCP resulting from any redemptions or exchanges of Units from the HSCP Members, and (ii) certain other tax benefits related to the Company making payments under the Tax Receivable Agreement and the Tax Receivable Bonus Plan. Although the actual timing and amount of any payments that the Company makes to the Tax Receivable Recipients cannot be estimated, it expects those payments will be significant. Any payments made by the Company to the Tax Receivable Recipients may generally reduce the amount of overall cash flow that might have otherwise been available to it. Payments under the Tax Receivable Agreement are not conditioned on any Tax Receivable Recipient's continued ownership of Units or our shares after the completion of the RTO. Payments under the Tax Receivable Bonus Plan may, at times, be conditioned on the Tax Receivable Recipient's continued employment by the Company. As of March 31, 2023, the Company has not made any payments in relation to the Tax Receivable Agreement or the Tax Receivable Bonus Plans.

Concurrently with the execution of the Floating Share Arrangement Agreement, Canopy Growth, Canopy USA, High Street, Acreage Holdings America, Inc. and certain individuals party to the Tax Receivable Agreement, amended the Tax Receivable Agreement in accordance with the Floating Share Agreement. Pursuant to the Floating Share Agreement, Canopy Growth, on behalf of Canopy USA agreed to: (i) issue Canopy Shares with a value of approximately \$30,500 to the Tax Receivable Agreement Members in exchange for each such individual executing an assignment of rights agreement assigning such individual's rights under the Tax Receivable Agreement to Canopy USA, such that following assignment, Canopy USA is the sole member and beneficiary under the Tax Receivable Agreement; and (ii) fund a payment with a value of approximately \$19,500 to be made by the Company in Canopy Shares to certain eligible participants pursuant to the Tax Receivable Bonus Plans, as amended on October 24, 2022, both in order to reduce a potential liability of approximately \$121,000 under the Tax Receivable Agreement and the Tax Receivable Bonus Plans. In connection with the foregoing, Canopy Growth issued 5,648,927 Canopy Shares on or about November 4, 2022 and 7,102,081 Canopy Shares on or about March 17, 2023 to the Tax Receivable Agreement Members. In addition, the Tax Receivable Agreement Bonuses with an aggregate value of approximately \$19,500 in Canopy Shares will be issued by Canopy to certain eligible participants under the Tax Receivable Bonus Plans on the closing of the Floating Share Arrangement or, if the Floating Share Arrangement does not close or is terminated but the Amended Arrangement closes, then on the closing of the acquisition. The Tax Receivable Agreement Bonuses will be paid to recipients to be determined by Kevin Murphy, the administrator of the Tax Receivable Bonus Plans, and may include one or more of Kevin Murphy, John Boehner, Brian Mulroney, and Peter Caldini, each of whom are directors of Acreage and other current and former officers or consultants of Acreage as may be determined by Kevin Murphy. Canopy Growth has also agreed to register the resale of such Canopy Shares under the Securities Act of 1933, as amended.

Debenture

In connection with the implementation of the Amended Arrangement, pursuant to a secured debenture dated September 23, 2020 (the "Debenture") issued by Universal Hemp, LLC, an affiliate of Acreage that operates solely in the hemp industry in full compliance with all applicable laws (the "Borrower"), to 11065220 Canada Inc., an affiliate of Canopy Growth (the "Lender"), the Lender agreed to provide a loan of up to \$100,000 (the "Loan"), \$50,000 of which was advanced on the Amendment Date (the "Initial Advance"), and \$50,000 of the Loan will be advanced in the event that the following conditions, among others, are satisfied: (a) the Borrower's EBITDA (as defined in the Debenture) for any 90 day period is greater than or equal to 2.0 times

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

the interest costs associated with the Initial Advance; and (b) the Borrower's business plan for the 12 months following the applicable 90 day period supports an Interest Coverage Ratio (as defined in the Debenture) of at least 2.00:1.

The principal amount of the Loan will bear interest from the date of advance, compounded annually, and be payable on each anniversary of the date of the Debenture in cash in U.S. dollars at a rate of 6.1% per annum. The Loan will mature 10 years from the date of the Initial Advance.

The Loan must be used exclusively for U.S. hemp-related operations and on the express condition that such amount will not be used, directly or indirectly, in connection with or for the operation or benefit of any of the Borrower's affiliates other than subsidiaries of the Borrower exclusively engaged in U.S. hemp-related operations and not directly or indirectly, towards the operation or funding of any activities that are not permissible under applicable law. The Loan proceeds must be segregated in a distinct bank account and detailed records of debits to such distinct bank account will be maintained by the Borrower.

No payment due and payable to the Lender by the Borrower pursuant to the Debenture may be made using funds directly or indirectly derived from any cannabis or cannabis-related operations in the United States, unless and until the Triggering Event Date.

The Debenture includes usual and typical events of default for a financing of this nature, including, without limitation, if: (i) Acreage is in breach or default of any representation or warranty in any material respect pursuant to the Arrangement Agreement; (ii) Operations deemed to be non-core must cease within 18 months from the Amendment Date; and (iii) Acreage fails to perform or comply with any covenant or obligation in the Arrangement Agreement which is not remedied within 30 days after written notice is given to the Borrower by the Lender. The Debenture also includes customary representations and warranties, positive covenants and negative covenants of the Borrower.

Advisor fee

In connection with the Prior Plan of Arrangement, the Company entered into an agreement with its financial advisor providing for a fee payment of \$7,000 in either cash, Acreage shares or Canopy Growth shares, at the discretion of the Company, upon the successful acquisition of Acreage by Canopy Growth. During the fourth quarter of 2022, the Company amended the terms of the agreement with its financial advisors providing for a fee payment of \$3,000 in cash, less a \$500 initial payment, and \$2,000 in shares of the Company, upon the successful acquisition of Acreage by Canopy Growth.

Surety bonds

The Company has indemnification obligations with respect to surety bonds primarily used as security against non-performance in the amount of \$5,000 as of March 31, 2023, for which no liabilities are recorded on the Unaudited Condensed Consolidated Statements of Financial Position.

The Company is subject to other capital commitments and similar obligations. As of March 31, 2023 and 2022, such amounts were not material.

CanWell Settlement

In November 2020, the Company entered into a final confidential settlement agreement with CanWell, LLC for certain outstanding proceedings. As part of that agreement, the Company accrued for \$7,750 in *Legal settlements, net* on the Statements of Operations for the year ended December 31, 2020. In connection with this settlement agreement, the Company issued a promissory note in the amount of \$7,750 to CanWell, which is non-interest bearing and is payable in periodic payments through December 31, 2024. Through March 31, 2023, the Company has paid \$4,583 of the promissory note.

Contingencies

The Company's operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company's applicable subsidiaries ceasing operations. While management of the Company believes that the Company's subsidiaries are in compliance with applicable local and state regulations as of March 31, 2023, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company's subsidiaries may be subject to regulatory fines, penalties, or restrictions in the future.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

The Company and its subsidiaries may be, from time to time, subject to various administrative, regulatory and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated.

New York outstanding litigation

On November 2, 2018, EPMMNY LLC ("EPMMNY") filed a complaint in the Supreme Court of the State of New York, County of New York, asserting claims against 16 defendants, including NYCANNA, Impire State Holdings LLC, NY Medicinal Research & Caring, LLC (each, a wholly-owned subsidiary of High Street) and High Street. The Index Number for the action is 655480/2018. EPMMNY alleges that it was wrongfully deprived of a minority equity interest and management role in NYCANNA by its former partner, New Amsterdam Distributors, LLC, which attempted to directly or indirectly sell or transfer EPMMNY's alleged interest in NYCANNA to other entities in 2016 and 2017, including Impire, NYMRC and High Street.

EPMMNY alleges that it is entitled to the value of its alleged minority interest in NYCANNA or minority ownership in NYCANNA. EPMMNY also alleges that certain defendants misused its alleged intellectual property and/or services, improperly solicited its employees, and aided and abetted or participated in the transfer of equity and/or business opportunities from EPMMNY.

High Street intends to vigorously defend this action, which the Company firmly believes is without merit. High Street is also entitled to full indemnity from the claims asserted against it by EPMMNY pursuant to the purchase agreement pertaining to its acquisition of NYCANNA and personal guarantee by the largest shareholders of the seller. High Street, along with the other defendants, filed a motion to dismiss on April 1, 2019. The motion was fully briefed and submitted to the Court as of July 18, 2019, and oral argument was heard on September 6, 2019. The motion remains pending before the Court. Following a hearing held during April 2022, the Court ruled that Plaintiff had the capacity to bring this action on behalf of EPMMNY. The motions to dismiss remain pending on all other grounds.

14. RELATED PARTY TRANSACTIONS

Transactions with related parties are entered into in the normal course of business and are measured at the amount established and agreed to by the parties.

6.10% Secured debenture due September 2030

As disclosed in Note 10, "6.10% Secured debenture due September 2030", on September 23, 2020, pursuant to the implementation of the Amended Arrangement, a subsidiary of Canopy Growth advanced gross proceeds of \$50,000 (less transaction costs of approximately \$4,025) to Universal Hemp, an affiliate of the Company, pursuant to the terms of a secured debenture. In accordance with the terms of the debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. Acreage then engaged an investment advisor (the "Investment Advisor") which, under the Investment Advisor's sole discretion, invested on behalf of Universal Hemp, \$34,019 of the proceeds on September 28, 2020. During the three months ended March 31, 2023, the Company incurred interest expense attributable to the 6.10% Secured debenture due September 2030 of \$763.

As a result of the transaction above, Universal Hemp, a subsidiary of the Company, acquired 34,019 class B units, at \$1 par value per unit, which represented 100% financial interest in an Investment Partnership, a Canada-based limited partnership. An affiliate of the Institutional Investor holds Class A Units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The class B units are held by the Institutional Investor as agent for Universal Hemp. On September 28, 2020, the Company received gross proceeds of \$33,000 (less transaction costs of approximately \$959) from an affiliate of the Institutional Lender (the "Lender") and used a portion of the proceeds of this loan to retire its short-term \$11,000 convertible note and its short-term note aggregating approximately \$18,000 in October 2020, with the remainder being used for working capital purposes. The Lender is controlled by the Institutional Lender. The Investment Partnership is the investor in the Lender.

Prime rate credit facilities due January 2026, as amended

On December 16, 2021, the Company entered into the Prime rate credit facilities due January 2026 with a syndicate of lenders, including Viridescent Realty Trust, Inc. ("Viridescent"), an entity controlled by Kevin Murphy. Refer to Note 10 for further discussion. On October 24, 2022, the Company amended these credit facilities and the Company paid an amendment fee of \$1,250 to the lenders, with \$375 paid to Viridescent.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

Viridescent has committed \$37,500 of the \$125,000 drawn down under the Credit Facility, with third-party syndicated affiliates committing the additional \$87,500. During the three months ended March 31, 2023, the Company incurred interest expense attributable to Viridescent of \$1,260. The loan is secured by first-lien mortgages on Acreage's wholly owned real estate and other commercial security interests. A third-party syndicate served as Administrative Agent for the transaction.

15. REPORTABLE SEGMENTS

The Company prepares its segment reporting on the same basis that its Chief Operating Decision Maker manages the business, and makes operating decisions. The Company operates under one operating segment, which is its only reportable segment: the production and sale of cannabis products. The Company's measure of segment performance is net income, and derives its revenue primarily from the sale of cannabis products, as well as related management or consulting services which were not material in all periods presented. All of the Company's operations are located in the United States.

16. EARNINGS PER SHARE

Basic earnings per share are computed by dividing net loss attributable to common shareholders of the Company by the weighted average number of outstanding shares for the period. Diluted earnings per share are calculated based on the weighted number of outstanding common shares plus the dilutive effect of stock options and warrants, as if they were exercised, and restricted stock units and profits interests, as if they vested and NCI convertible units, as if they converted.

Basic and diluted loss per share is as follows:

| | Three Months Ended March 31, | | | | | | |
|---|------------------------------|----------|------|----------|--|--|--|
| | | 2023 | 2022 | | | | |
| Net loss attributable to common shareholders of the Company | \$ | (14,590) | \$ | (12,694) | | | |
| Weighted average shares outstanding - basic | | 112,546 | | 106,900 | | | |
| Effect of dilutive securities | | _ | | _ | | | |
| Weighted average shares - diluted | | 112,546 | | 106,900 | | | |
| Net loss per share attributable to common shareholders of the Company - basic | \$ | (0.13) | \$ | (0.12) | | | |
| Net loss per share attributable to common shareholders of the Company - diluted | \$ | (0.13) | \$ | (0.12) | | | |

During the three months ended March 31, 2023, 5,817 Fixed warrants, 2,524 Floating warrants, 6,206 Fixed Share RSUs, 449 Floating Share RSUs, 7,337 Fixed Share stock options, 2,236 Floating Share stock options and 22,698 NCI convertible units were excluded from the calculation of net loss per share attributable to common shareholders of the Company - diluted, as they were anti-dilutive. During the three months ended March 31, 2022, 5,817 Fixed warrants, 2,524 Floating warrants, 2,916 Fixed Share RSUs, 1,251 Floating Share RSUs, 1,525 Fixed Share stock options, 2,413 Floating Share stock options and 22,698 NCI convertible units were excluded from the calculation of net loss per share attributable to common shareholders of the Company - diluted, as they were anti-dilutive.

ACREAGE HOLDINGS, INC. NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except per share data)

17. SUBSEQUENT EVENTS

On April 11, 2023, the Company sold, for total proceeds of \$12,113, the rights to receive certain Employee Retention Tax Credits ("ERTC") with an aggregate receivable value of \$14,251. In the event that all or a portion of the ERTC are a) objected to by the IRS or otherwise asserted by the IRS to be, unenforceable or invalid, b) impaired by the commencement by the IRS of any action or proceeding including, but not limited to any proceeding which seeks to reduce all or part of the Claim Amount, or c) offset or setoff against unpaid taxes of the Company, disallowed, reduced, subordinated or otherwise impaired by action of the IRS, in whole or in part for any reason whatsoever, the purchaser shall have the right to put all or a portion of the purchased ERTC back to the Company plus interest thereon at ten percent per annum.

On April 13, 2023, Health Circle, Inc. (the "Borrower") filed a civil action in the Massachusetts Superior Court of Plymouth County against the Company and MA RMD SVCS, LLC (the "Lender"), related to the parties' Revolving Line of Credit Agreement, and has alleged breach of contract, breach of the implied covenant of good faith and fair dealing, fraud, and a violation of G.L. c. 93A. The filing of this preemptive "strike suit" follows the Company's continuing efforts to recover the principal and interest payments owed to the Company by Borrower under the Revolving Line of Credit Agreement. The Company believes Health Circle's allegations to be without merit and intends to respond to the complaint and to assert its own claims against Borrower and its principal(s) for their failure to repay their debt under the terms of the Credit Agreement.

On April 28, 2023, the Company reached an agreement with the lenders of the Prime rate credit facilities due January 2026 that would allow it to draw a further \$15,000 under its current Credit Agreement, but such funds would be maintained in a segregated account until dispersed and be restricted for use to only eligible capital expenditures. As part of this agreement, the Company has agreed to limit the total amounts outstanding under the Credit Agreement to \$140,000 and to, at all times subsequent to the amendment, maintain collateral (as defined in the Credit Agreement) equal to or greater than the outstanding amount under the Credit Agreement. Refer to Note 10 for further discussion.

Management has reviewed all other events subsequent to March 31, 2023 through the date of issuing these financial statements and determined that no further subsequent events require adjustment or disclosure.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to assist in the understanding and assessing the trends and significant changes in our results of operations and financial condition. Historical results may not be indicative of future performance. This discussion includes forward-looking statements that reflect our plans, estimates and beliefs. Such statements involve risks and uncertainties. Our actual results may differ materially from those contemplated by these forward-looking statements as a result of various factors, including those set forth in "Risk Factors" in Part I, Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2022 (the "2022 Form 10-K"), and "Cautionary Statement Regarding Forward-Looking Statements" set forth below.

This MD&A should be read in conjunction with the Company's unaudited condensed consolidated financial statements and for the three month period ended March 31, 2023 and related notes appearing elsewhere in this Quarterly Report on Form 10-Q (this "Quarterly Report" or "Form 10-Q) and the 2022 Form 10-K. Financial information presented in this MD&A is presented in thousands of U.S. dollars, unless otherwise indicated.

Cautionary Statement Regarding Forward Looking-Statements

This Quarterly Report of the Company contains statements that include forward-looking information and are forward-looking statements within the meaning of applicable Canadian and United States securities legislation ("forward-looking statements"), including the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. All statements, other than statements of historical fact, included herein are forward-looking statements, including, for greater certainty, statements regarding the proposed transactions with Canopy Growth Corporation ("Canopy Growth or "Canopy"), including the anticipated benefits and likelihood of completion thereof.

Generally, forward-looking statements may be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "proposed", "is expected", "budgets", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. There can be no assurance that such forward-looking statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking statements. Forward-looking statements reflect Acreage's current beliefs and are based on information currently available to Acreage and on assumptions Acreage believes are reasonable. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Acreage to be materially different from those expressed or implied by such forward-looking statements. Such risks and other factors may include, but are not limited to:

- The US Federal Illegality of the Company's Business Activities
- the anticipated benefits of the Floating Share Arrangement with Canopy Growth;
- the likelihood of Canopy Growth completing the acquisition of the Fixed Shares and/or Floating Shares;
- risks related to the ability to finance Acreage's business and fund its obligations;
- other expectations and assumptions concerning the transactions contemplated between Canopy Growth and Acreage;
- in the event that the Floating Share Arrangement is completed, the likelihood of Canopy completing the Acquisition in accordance with the Existing Arrangement Agreement;
- the risk of a change of control of either Canopy or Canopy USA;
- the impact of material non-recurring expenses in connection with the Floating Share Arrangement on Acreage's future results of operations, cash flows and financial condition;
- the ability of Canopy, Canopy USA and Acreage to leverage each other's respective capabilities and resources;
- the available funds of Acreage and the anticipated use of such funds;
- the availability of financing opportunities for Acreage and the risks associated with the completion thereof;
- · regulatory and licensing risks;
- changes in general economic, business and political conditions, including changes in the financial and stock markets;
- legal and regulatory risks inherent in the cannabis industry;
- risks associated with economic conditions, dependence on management and currency risk;
- risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks;
- risks relating to anti-money laundering laws and regulation;
- other governmental and environmental regulation;
- public opinion and perception of the cannabis industry;
- risks related to contracts with third-party service providers;
- risks related to the enforceability of contracts and lack of access to U.S. bankruptcy protections;
- reliance on the expertise and judgment of senior management of Acreage;
- risks related to proprietary intellectual property and potential infringement by third parties;
- the concentrated voting control of Acreage's founder and the unpredictability caused by Acreage's capital structure;

- the dual structure of the Fixed and Floating Shares
- risks relating to the management of growth;
- increasing competition in the industry;
- risks inherent in an agricultural business;
- risks relating to energy costs:
- · risks associated with cannabis products manufactured for human consumption including potential product recalls;
- reliance on key inputs, suppliers and skilled labor;
- cybersecurity risks;
- ability and constraints on marketing products;
- fraudulent activity by employees, contractors and consultants;
- tax and insurance related risks:
- risks related to the economy generally;
- risk of litigation;
- conflicts of interest;
- risks relating to certain remedies being limited and the difficulty of enforcement judgments and effecting service outside of Canada;
- · risks related to future acquisitions or dispositions;
- sales by existing shareholders; and
- limited research and data relating to cannabis.

A description of additional assumptions used to develop such forward-looking statements and a description of additional risk factors that may cause actual results to differ materially from forward-looking statements can be found in Part I, Item 1A of the Company's Annual Report on Form 10-K, under the heading "Risk Factors", dated May 1, 2023, as filed with the Securities and Exchange Commission. Although Acreage has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking statements contained in this Form 10-Q are expressly qualified by this cautionary statement. The forward-looking statements contained in this Form 10-Q represent the expectations of Acreage as of the date of this Form 10-Q and, accordingly, are subject to change after such date. However, Acreage expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Management's discussion and analysis of financial condition and results of operations is intended to help provide an understanding of the Company's financial condition, changes in financial condition and results of operations. This discussion is organized as follows:

- Overview—This section provides a general description of the Company's businesses, its strategic objectives, as well as developments that occurred during the three months ended March 31, 2023 and 2022 that the Company believes are important in understanding its results of operations and financial condition or to disclose known trends.
- Results of Operations—This section provides an analysis of the Company's results of operations for the three months ended March 31, 2023 and 2022. This analysis is presented on a consolidated basis. In addition, a brief description is provided of significant transactions and events that impact the comparability of the results being analyzed.
- Liquidity and Capital Resources—This section provides an analysis of the Company's cash flows for the three months
 ended March 31, 2023 and 2022, as well as a discussion on the Company's outstanding debt and commitments that
 existed as of March 31, 2023. Included in the discussion of outstanding debt is a discussion of the amount of financial
 capacity available to fund the Company's future commitments and obligations, as well as a discussion of other
 financing arrangements.

Overview

Acreage, a vertically integrated, multi-state operator of cannabis licenses and assets in the U.S, was continued into the Province of British Columbia under the *Business Corporations Act* (British Columbia). Acreage Fixed Shares and Floating Shares (as such terms are defined at Note 13 of the unaudited condensed consolidated financial statements) are each listed on the Canadian Securities Exchange under the symbols "ACRG.A.U" and "ACRG.B.U", respectively, and are quoted on the OTCQX® Best Market by OTC Markets Group under the symbols "ACRHF" and "ACRDF", respectively and on the Open Market of the Frankfurt Stock Exchange under the symbols "0VZ1" and "0VZ2", respectively. Acreage operates through its consolidated subsidiary High Street Capital Partners, LLC ("HSCP"), a Delaware limited liability company. HSCP, which does business as "Acreage Holdings", was formed on April 29, 2014. The Company became an indirect parent of HSCP on November 14, 2018 in connection with a reverse takeover ("RTO") transaction. The Company's operations include (i) cultivating cannabis plants, (ii) manufacturing branded consumer products, (iii) distributing cannabis flower and manufactured products, and (iv) retailing high-quality, effective and dosable cannabis products to consumers. The Company appeals to medical and adult-use customers through brand strategies intended to build trust and loyalty.

As of March 31, 2023, Acreage owned and operated a total of twenty-three dispensaries - four in New York, three in New Jersey, three in Connecticut, two in Massachusetts, two in Illinois, five in Ohio, and four in Maine. As of March 31, 2023, Acreage owned and operated a total of nine cultivation and processing facilities, one each in California, Illinois, Maine, New Jersey, New York, Ohio and Pennsylvania, respectively, and two in Massachusetts.

Strategic Priorities

The Company believes its focused strategy is the key to continued improvements in its financial results and shareholder value. For the past few years, the Company was focused on three key strategic objectives - accelerating growth in its core markets, driving profitability, and strengthening the balance sheet. For 2023 and onwards, the Company has modified its strategic objectives in response to Company and industry developments - focus on cash, accelerate growth in core markets with core brands and prepare for Canopy USA.

Focus on Cash: A combination of economic conditions, lack of regulatory change and industry competition impacting pricing has negatively impacted the Company's ability to generate cash flow to support operational requirements and capital activities. Additionally, these factors have likely limited the additional capital that might be available to the Company. While these factors continue, the Company will focus on maximizing the cash flow generated by operating activities and limit capital expenditures to only those projects that can be funded from existing resources and are expected to generate near-term returns.

Accelerating Growth in Core Markets with Core Brands: Through prior acquisitions and capital expenditures, management believes Acreage is well positioned for future success in several key markets as regulations regarding the use of cannabis continue to evolve. The Company will continue to focus its growth on its core markets where it can take advantage of and expand on the presence already established. Additionally, the Company has developed a portfolio of core brands that resonate with its customers. The Company will focus on ensuring that these core brands feature prominently in the markets where they are available.

Prepare for Canopy USA: During the fourth quarter of 2022, the Company entered into a new strategic arrangement with Canopy Growth that, would allow Canopy Growth to acquire 100% of Acreage by (i) waiving its existing Floating Share option and entering into a new Floating Share acquisition agreement; and (ii) committing to exercise its Fixed Share option, all subject to required approvals and terms of the related agreements. Throughout 2023, the Company will take all steps necessary to prepare for the eventual closing of this transactions.

Highlights from the three months ended March 31, 2023:

- The Company's total consolidated revenue declined 2% as compared with the three months ended March 31, 2022. After adjusting for acquisitions and divestitures, revenue for the 3 months ended March 31, 2023 was relatively consistent with the comparable period in the prior year.
- Adjusted EBITDA for the three months ended March 31, 2023 was \$10.6 million, compared to adjusted EBITDA of \$8.6 million during the same period in 2022. Excluding the impact of the reversal of bonus provisions related to the prior year, adjusted EBITDA for the three months ended March 31, 2023 was \$6.3 million. This marks nine consecutive quarters of positive adjusted EBITDA, further validating management's refocused strategic plan. Refer to section "Non-GAAP Information" for a discussion of Adjusted EBITDA as a non-GAAP measure.
- On January 2, 2023, the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company's operations in Maine.

- On January 10, 2023, the Company commenced adult-use operations in Connecticut, offering a range of products from our flagship brand The Botanist for adult-use sales in Montville.
- On January 31, 2023, the Company launched "Fast-Acting Gummies" or "TiME Gummies" under its flagship brand The Botanist in Illinois, Maine, Massachusetts, and Ohio.
- The Floating Share Arrangement was approved at a special meeting of the holders of Floating Shares held on March 15, 2023. Refer to Note 13 for further discussion.

Operational and Regulation Overview (all amounts in thousands, except per share amounts)

The Company believes its operations are in material compliance with all applicable state and local laws, regulations and licensing requirements in the states in which it operates. However, cannabis is illegal under U.S. federal law. Substantially all of the Company's revenue is derived from U.S. cannabis operations. For information about risks related to U.S. cannabis operations, please refer to Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

Results of Operations

The following table presents selected financial data derived from the unaudited condensed consolidated financial statements of the Company for the three months ended March 31, 2023 and 2022. The selected financial information set out below may not be indicative of the Company's future performance.

Summary Results of Operations

| | | | | | Better/(Worse) |) | | |
|--|----|----------------|------|--------------|----------------|------|--|--|
| in thousands, except per share amounts | | Three Months I | Ende | ed March 31, | 2023 vs. 2022 | | | |
| | | 2023 | | 2022 | \$ | % | | |
| Revenues, net | \$ | 55,963 | \$ | 56,879 | \$ (916) | (2)% | | |
| Net operating income (loss) | | 1,145 | | (2,722) | 3,867 | n/m | | |
| Net loss attributable to Acreage | | (14,590) | | (12,694) | (1,896) | (15) | | |
| Basic and diluted loss per share attributable to Acreage | \$ | (0.13) | \$ | (0.12) | \$ (0.01) | (8)% | | |

Revenues, Cost of goods sold and Gross profit

The Company derives its revenues from sales of cannabis and cannabis-infused products through retail dispensary, wholesale and manufacturing and cultivation businesses, as well as from management or consulting fees from entities for whom the Company provides management or consulting services.

Gross profit is revenue less cost of goods sold. Cost of goods sold includes costs directly attributable to inventory sold such as direct material, labor, and overhead, including depreciation. Such costs are further affected by various state regulations that limit the sourcing and procurement of cannabis and cannabis-related products, which may create fluctuations in gross profit over comparative periods as the regulatory environment changes.

| | | | | | | Better/(Wors | se) | |
|-------------------------------|----|--------------|-------|-------------|---------------|--------------|-------|--|
| in thousands | Т | Three Months | Ended | l March 31, | 2023 vs. 2022 | | | |
| | | 2023 | | 2022 | | \$ | % | |
| Retail revenue, net | \$ | 41,881 | \$ | 41,427 | \$ | 454 | 1 % | |
| Wholesale revenue, net | | 13,998 | | 15,172 | | (1,174) | (8) | |
| Other revenue, net | | 84 | | 280 | | (196) | (70) | |
| Total revenues, net | \$ | 55,963 | \$ | 56,879 | \$ | (916) | (2)% | |
| Cost of goods sold, retail | | (20,414) | | (20,768) | | 354 | 2 | |
| Cost of goods sold, wholesale | | (8,964) | | (6,601) | | (2,363) | (36) | |
| Total cost of goods sold | \$ | (29,378) | \$ | (27,369) | \$ | (2,009) | (7)% | |
| Gross profit | \$ | 26,585 | \$ | 29,510 | \$ | (2,925) | (10)% | |
| Gross margin | | 48 % |) | 52 % | | | (4)% | |

n/m - Not Meaningful

Three months ended March 31, 2023 vs. 2022

Total revenues for the three months ended March 31, 2023 declined by \$916, or 2%, compared to the three months ended March 31, 2022. The decline in total revenue was primarily due to a decrease of \$1,238 related to the divestiture of the Company's operations in Oregon, offset by an increase of \$485 due to the acquisitions of a Maine dispensary in 2022. Excluding these acquisitions and divestitures, total revenue decreased by \$163 for the three months ended March 31, 2023, as compared to 2022.

Retail revenue for the three months ended March 31, 2023 grew by \$454, or 1%, compared to the three months ended March 31, 2022. Excluding the impact of acquisitions and divestitures, retail revenue increased by \$1,208, or 3%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. This organic growth was primarily driven by the commencement of adult use sales in New Jersey in April 2022 and Connecticut in January 2023.

Wholesale revenue for the three months ended March 31, 2023 decreased by \$1,174, or 8%, compared to the three months ended March 31, 2022. The decline in wholesale revenue was primarily due to price compression and decreased wholesale demand in select markets, particularly in those markets where integrated operators put a greater focus on the sales of their own internally produced products.

Retail cost of goods sold increased \$354, or 2%, for the three months ended March 31, 2023 compared to 2022, which was generally consistent with the 1% increase in retail revenue. Price compression in select markets was offset by cost efficiencies.

Wholesale cost of goods sold increased \$2,363, or 36%, for the three months ended March 31, 2023 compared to 2022, which outpaced the 8% decrease in wholesale revenue. Wholesale cost of goods sold increased due to \$2,237 of non-cash inventory adjustments made during the three months ended March 31, 2023 as a result of excess inventory in select markets, reducing the carrying value of wholesale inventory to reflect the lower of cost and net realizable value. Excluding these non-cash inventory adjustments, wholesale costs of goods sold increased \$129 or 2%. Cost increases and product mix shifts drove the increase in wholesale cost of goods sold.

Gross profit decreased \$2,925, or 10%, for the three months ended March 31, 2023 to \$26,585 from \$29,510 in 2022, and Gross margin decreased from 52% of revenue for the three months ended March 31, 2022 to 48% of revenue in 2023, or 4%, due to the factors discussed above. Efficiencies gained from further economies of scale were unable to offset overall selling price declines, cost increases due to inflation, and the aforementioned wholesale non-cash inventory adjustments. Excluding the non-cash inventory adjustments, margin decreased slightly to 51%.

Revenue by geography

While the Company operates under one operating segment for the production and sale of cannabis products, the below revenue breakout by geography is included as management believes it provides relevant and useful information to investors.

| Revenue by region | | | | | Better/(Wors | se) | | |
|---------------------|----------------|-------|-----------|---------------|--------------|------|--|--|
| in thousands | Three Months F | Ended | March 31, | 2023 vs. 2022 | | | | |
| | 2023 | | 2022 | | \$ | % | | |
| New England | 15,088 | \$ | 16,426 | \$ | (1,338) | (8)% | | |
| Mid-Atlantic | 20,276 | | 15,355 | | 4,921 | 32 | | |
| Midwest | 20,317 | | 23,169 | | (2,852) | (12) | | |
| West | 282 | | 1,929 | | (1,647) | (85) | | |
| Total revenues, net | 55,963 | \$ | 56,879 | \$ | (916) | (2)% | | |

Total operating expenses

Total operating expenses consist primarily of loss on impairments, compensation expense at our corporate offices as well as operating subsidiaries, professional fees, which includes, but is not limited to, legal and accounting services, depreciation and other general and administrative expenses.

| Operating expenses | Better/(Worse) | | | | | | | |
|---|----------------|----------------|------|--------------|----|---------------|-------|--|
| in thousands | | Three Months I | Ende | ed March 31, | | 2023 vs. 2022 | | |
| | | 2023 | | 2022 | | \$ | % | |
| General and administrative | \$ | 10,512 | \$ | 8,387 | \$ | (2,125) | (25)% | |
| Compensation expense | | 12,203 | | 14,195 | | 1,992 | 14 | |
| Equity-based compensation expense | | 984 | | 4,159 | | 3,175 | 76 | |
| Marketing | | 744 | | 697 | | (47) | (7) | |
| Impairments, net | | _ | | 2,138 | | 2,138 | n/m | |
| Write down (recovery) of assets held-for-sale | | _ | | 874 | | 874 | n/m | |
| Legal settlements (recoveries) | | _ | | (25) | | (25) | n/m | |
| Depreciation and amortization | | 997 | | 1,807 | | 810 | 45 | |
| Total operating expenses | \$ | 25,440 | \$ | 32,232 | \$ | 6,792 | 21 % | |
| n/m - Not Meaningful | | | | | | | | |

Three months ended March 31, 2023 vs. 2022

Total operating expenses for the three months ended March 31, 2023 were \$25,440, an decrease of \$6,792, or 21%, compared with 2022. The primary drivers of the increase in operating expenses were as follows:

- General and administrative expenses increased \$2,125 during the three months ended March 31, 2023 compared with 2022, primarily due to increases in (i) the cost of insurance, fees, permits and licenses, (ii) bad debt expenses of \$1,250 related to the write-off of previously recognized management fees which are not collectible, (iii) increased travel as restrictions have been lifted and (iv) increased office expenses.
- Compensation expense decreased \$1,992 during the three months ended March 31, 2023 as compared with 2022, primarily due to the reversal of bonus provisions related to the prior year.
- Equity-based compensation expense decreased \$3,175, or 76%, during the three months ended March 31, 2023 as compared with 2022, primarily due to the fully vesting, prior to the three months ended March 31, 2023 of certain historic equity-based compensation grants and no annual grants have been issued to employees during 2023 under the Company's normal long-term incentive plan.
- There were no impairments in the three months ended March 31, 2023. The impairments in the comparative period of 2022 are primarily due to an impairment of \$1,907 related to certain Michigan locations as the Company was unsuccessful in finding a satisfactory buyer for these assets which were previously classified as held-for-sale.
- There were no write downs or recoveries of assets held-for-sale in the three months ended March 31, 2023. The write downs of assets held-for-sale in the comparative period of 2022 relate to the Company's Oregon operations which were disposed of in the year ended December 31, 2022.
- Depreciation and amortization expenses decreased by \$810 during the three months ended March 31, 2023 compared with 2022, primarily due to an acceleration of the amortization of certain intangible assets as a result of a reduction in the expected useful lives of such assets during the three months ended March 31, 2022 and due to the impairment of certain intangible assets in the year ended December 31, 2022.

Total other income (loss)

| Other income (loss) | | | | | | Better/(Wor | se) | |
|---------------------------------------|----|--------------|------|-----------|---------------|-------------|--------|--|
| in thousands | Tl | ree Months E | nded | March 31, | 2023 vs. 2022 | | | |
| | | 2023 | | 2022 | | \$ | % | |
| Income (loss) from investments, net | \$ | (342) | \$ | 1,133 | \$ | (1,475) | n/m | |
| Interest income from loans receivable | | 16 | | 417 | | (401) | (96)% | |
| Interest expense | | (8,074) | | (4,781) | | (3,293) | (69) | |
| Other loss, net | | (1,553) | | (10) | | (1,543) | n/m | |
| Total other loss | \$ | (9,953) | \$ | (3,241) | \$ | (6,712) | (207)% | |
| n/m - Not Meaningful | | | | | | | | |

Three months ended March 31, 2023 vs. 2022

Total other loss for the three months ended March 31, 2023 was \$9,953, an increase of \$6,712 compared with 2022. The primary drivers of the decrease in Total other income (loss) were as follows:

- Loss from investments, net of \$342 for the three months ended March 31, 2023 has decreased \$1,475 as compared with 2022 due to fair value adjustments to the investment in equity in other companies.
- Interest income from loans receivable of \$16 for the three months ended March 31, 2023 has declined \$401 as compared with 2022 due to a reduction in loans receivable outstanding during the comparative period.
- Interest expense for the three months ended March 31, 2023 of \$8,074 increased by \$3,293 as a result of the Company
 having a larger debt balance as compared to 2022 and due to an increased interest rate on a substantial portion of the
 Company's debt.
- Other loss for the three months ended March 31, 2023 of \$1,553 increased by \$1,543 as compared with 2022. Other income, net for the year ended March 31, 2023 was primarily due to a loss on the termination of a lease related the Company's operations in Massachusetts.

Net loss

| Net loss | Better/(Worse) | | | | | | | |
|--|--------------------|------|-------------|----|---------------|---|-------|--|
| in thousands | Three Months E | ndec | d March 31, | | 2023 vs. 2022 | | | |
| | 2023 2022 | | | | \$ | % | | |
| Net loss | \$ (16,157) | \$ | (13,911) | \$ | (2,246) | | (16)% | |
| Less: net loss attributable to non-controlling interests | (1,567) | | (1,217) | | (350) | | (29) | |
| Net loss attributable to Acreage Holdings, Inc. | \$ (14,590) | \$ | (12,694) | \$ | (1,896) | | (15)% | |

The changes in net loss are driven by the factors discussed above.

Non-GAAP Information

This statement includes Adjusted EBITDA, which is a non-GAAP performance measure that we use to supplement our results presented in accordance with U.S. GAAP. The Company uses Adjusted EBITDA to evaluate its actual operating performance and for planning and forecasting future periods. The Company believes that the adjusted results presented provide relevant and useful information for investors because they clarify the Company's actual operating performance, make it easier to compare our results with those of other companies and allow investors to review performance in the same way as our management. Since these measures are not calculated in accordance with U.S. GAAP, they should not be considered in isolation of, or as a substitute for, net loss or our other reported results of operations as reported under U.S. GAAP as indicators of our performance, and they may not be comparable to similarly named measures from other companies.

The Company defines Adjusted EBITDA as net income before interest, income taxes and, depreciation and amortization and excluding the following: (i) income from investments, net (the majority of the Company's investment income relates to remeasurement to net asset value of previously-held interests in connection with our roll-up of affiliates, and the Company expects income from investments to be a non-recurring item as its legacy investment holdings diminish), (ii) equity-based compensation expense, (iii) non-cash impairment losses, (iv) transaction costs, (v) non-cash inventory adjustments and (vi) other non-recurring expenses (other expenses and income not expected to recur).

Adjusted EBITDA Better/(Worse)

| in thousands | T | hree Months F | nded | March 31, | 2023 vs. 2022 | | | |
|---|----|----------------------|------|-----------|---------------|-------|------|--|
| | | 2023 | | 2022 | \$ | | % | |
| Net loss (U.S. GAAP) | \$ | (16,157) | \$ | (13,911) | | | | |
| Income tax expense | | 7,349 | | 7,948 | | | | |
| Interest expense, net | | 8,058 | | 4,364 | | | | |
| Depreciation and amortization ⁽¹⁾ | | 3,038 | | 2,891 | | | | |
| EBITDA (non-GAAP) | \$ | 2,288 | \$ | 1,292 | \$ | 996 | 77 % | |
| Adjusting items: | | | | | | | | |
| Loss (income) from investments, net | | 342 | | (1,133) | | | | |
| Impairments, net | | _ | | 1,956 | | | | |
| Non-cash inventory adjustments | | 2,237 | | _ | | | | |
| Loss on extraordinary events ⁽²⁾ | | 1,492 | | 182 | | | | |
| | | | | | | | | |
| Write down (recovery) of assets held-for-sale | | _ | | 874 | | | | |
| Legal settlements, net | | _ | | (25) | | | | |
| Gain on business divestiture | | _ | | (4) | | | | |
| Equity-based compensation expense | | 984 | | 4,159 | | | | |
| Other non-recurring expenses ⁽³⁾ | | 3,250 | | 1,326 | | | | |
| Adjusted EBITDA (non-GAAP) | \$ | 10,593 | \$ | 8,627 | \$ | 1,966 | 23 % | |

⁽¹⁾ Depreciation and amortization for the three months ended March 31, 2023 and 2022 contains depreciation and amortization included in cost of goods sold.

The increases in adjusted EBITDA are driven by the factors discussed above.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity

Sources and uses of cash (all amounts in thousands, except per share amounts)

The Company's primary uses of capital include operating expenses, income taxes, capital expenditures and the servicing of outstanding debt. The Company's primary sources of capital include funds generated by cannabis sales as well as financing activities. Through March 31, 2023, the Company had primarily used private financing as a source of liquidity for short-term working capital needs and general corporate purposes.

As of March 31, 2023, the Company had cash of \$14,251. The Company's ability to fund its operations, capital expenditures, acquisitions, and other obligations depends on its future operating performance and ability to obtain financing, which are subject to prevailing economic conditions, as well as financial, business and other factors, some of which are beyond the Company's control.

The Company's future contractual obligations include the following:

Leases

As of March 31, 2023, the Company had future operating lease obligations and future finance lease obligations of \$34,221 and \$16,212, respectively, with \$3,359 and \$677 payable within the next nine months, respectively. The Company leases land, buildings, equipment and other capital assets which it plans to use for corporate purposes in addition to the production and sale of cannabis products. Leases with an initial term of 12 months or less are not recorded on the Unaudited Condensed Consolidated Statements of Financial Position and are expensed in the Unaudited Condensed Consolidated Statements of Operations on the straight-line basis over the lease term. The Company does not have any material variable lease payments, and accounts for non-lease components separately from leases. Refer to Note 8 of the Unaudited Condensed Consolidated Financial Statements for further discussion.

Debt

⁽²⁾ Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence.

⁽³⁾ Other non-recurring expenses relates to certain compensation, general and administrative, and other miscellaneous expenses. The Company excludes these items as they are not expected to recur.

As of March 31, 2023, the Company had outstanding debt with varying maturities for an aggregate principal amount of \$216,937 (net of \$15,465 of unamortized discounts and debt issuance costs), with \$1,583 payable within the remaining nine months. The Company has related future interest payments of \$73,514, with \$16,279 payable within the remaining nine months. In April 2023, the Company reached an agreement with its lenders that would allow it to draw a further \$15,000 under its current credit agreement, but such funds would be restricted for use to only eligible capital expenditures. As part of this agreement, the Company agreed to not draw additional funds under the Credit Agreement. Refer to Notes 10 and 17 of the Unaudited Condensed Consolidated Financial Statements for further discussion.

The Company expects that its total readily available funds of \$14,251 as of March 31, 2023 and its further ability to obtain private and/or public financing, will be adequate to support the future obligations discussed above as well as the capital needs of the existing operations and expansion plans over the next twelve months. Additionally, the Company has a further \$15,000 of long-term debt available from its committed debt facilities, but such funds are restricted for use to only eligible capital expenditures. Further, in February 2023, the Company filed for certain Employee Retention Tax Credits ("ERTC") and it expects to receive approximately \$15,000, less applicable agent fees and other expenses. On April 11, 2023, the Company sold, with recourse, the rights to receive certain Employee Retention Tax Credits ("ERTC") with an aggregate receivable value of \$14.3 million for total proceeds of \$12.1 million. Refer to Note 2 of the Consolidated Financial Statements for further discussion.

Cash flows

Cash and cash equivalents were \$14,251 as of March 31, 2023, which represents a net decrease of \$9,816 for the three months ended March 31, 2023. The following table details the change in cash, cash equivalents, restricted cash and cash related to assets held for sale for the three months ended March 31, 2023 and 2022.

| | | | | | Better/(Wor | ·se) | |
|----|--------------|---------------------------------------|----------------------------|---|--|--|--|
| Th | ree Months E | Ende | d March 31, | | 2023 vs. 2022 | | |
| | 2023 | | 2022 | | \$ | % | |
| \$ | (8,070) | \$ | (5,363) | \$ | (2,707) | (50)% | |
| | (1,714) | | (6,066) | | 4,352 | 72 | |
| | (32) | | (11) | | (21) | (191) | |
| \$ | (9,816) | \$ | (11,440) | \$ | 1,624 | 14 % | |
| | \$ | 2023 \$ (8,070) (1,714) (32) | \$ (8,070) \$ (1,714) (32) | \$ (8,070) \$ (5,363) (1,714) (6,066) (32) (11) | 2023 2022 \$ (8,070) \$ (5,363) \$ (1,714) (6,066) (32) (11) | Three Months Ended March 31, 2023 vs. 20 \$ (8,070) \$ (5,363) \$ (2,707) (1,714) (6,066) 4,352 (32) (11) (21) | |

n/m - Not Meaningful

Net cash used in operating activities

During the three months ended March 31, 2023, the Company used \$8,070 of net cash in operating activities, which represented an increase of \$2,707, or 50%, when compared with 2022. Although the reported net loss increased by \$2,246 during the three months ended March 31, 2023 when compared to the same period of 2022, the net loss excluding non-cash items such as impairments, equity-based compensation, write-offs and recoveries, gains and losses on disposals and depreciation and amortization increased by \$3,656 when compared to the same period of 2022.

Net cash used in investing activities

During the three months ended March 31, 2023, the Company used \$1,714 of net cash through investing activities compared to \$6,066 of net cash used in investing activities in the same period for 2022, which represented an improvement of \$4,352. Net cash used in investing activities for the three months ended March 31, 2023 included \$2,230 on the purchase of capital assets and intangibles which was partially offset by cash acquired through business acquisitions of \$516.

Net cash used in financing activities

During the three months ended March 31, 2023, the Company used \$32 of net cash through financing activities compared to \$11 of net cash used in financing activities in the same period for 2022, which represented a change of \$21. Net cash used in financing activities for the three months ended March 31, 2023 included \$32 of debt repayments.

Capital Resources

Capital structure and debt

Our debt outstanding as of March 31, 2023 and December 31, 2022 is as follows:

| Debt balances | Mar | March 31, 2023 | | December 31, 2022 | |
|---|-----|----------------|----|--------------------------|--|
| Financing liability (failed sale-leaseback) | \$ | 15,253 | \$ | 15,253 | |
| Finance lease liabilities | | 5,982 | | 5,306 | |
| 7.50% Loan due April 2026 | | 31,418 | | 31,288 | |
| 6.10% Secured debenture due September 2030 | | 46,614 | | 46,502 | |
| Note due December 2024 | | 3,167 | | 3,167 | |
| Prime rate credit facilities due January 2026, as amended | | 114,503 | | 113,564 | |
| Total debt | \$ | 216,937 | \$ | 215,080 | |
| Less: current portion of debt | | 1,689 | | 1,584 | |
| Total long-term debt | \$ | 215,248 | \$ | 213,496 | |

Commitments and contingencies

Commitments

The Company provides revolving lines of credit to several third parties. Refer to Note 6 of the Unaudited Condensed Consolidated Financial Statements for further discussion.

Arrangement with Canopy Growth

On June 19, 2019, the shareholders of the Company and of Canopy Growth separately approved the Prior Plan of Arrangement involving the two companies. Subsequently, on September 23, 2020, Acreage and Canopy Growth entered into an amending agreement and the Amended Arrangement became effective on September 23, 2020.

During the fourth quarter of 2022, the Company entered into a new strategic arrangement with Canopy Growth that, would allow Canopy Growth to acquire 100% of Acreage by (i) waiving its existing Floating Share option and entering into a new Floating Share acquisition agreement; and (ii) committing to exercise its Fixed Share option, all subject to required approvals and terms of the related agreements.

Refer to Note 13 of the Unaudited Condensed Consolidated Financial Statements for further discussion.

Advisor fee

In connection with the Prior Plan of Arrangement, the Company entered into an agreement with its financial advisor providing for a fee payment of \$7,000 in either cash, Acreage shares or Canopy Growth shares, at the discretion of the Company, upon the successful acquisition of Acreage by Canopy Growth. During the fourth quarter of 2022, the Company amended the terms of the agreement with its financial advisors providing for a fee payment of \$3,000 in cash, less a \$500 initial payment, and \$2,000 in shares of the Company, upon the successful acquisition of Acreage by Canopy Growth.

Tax Receivable Agreement

The Company is a party to (i) a tax receivable agreement dated November 14, 2018 and subsequently amended (the "Tax Receivable Agreement") between the Company, certain current and former unit holders of HSCP and, Canopy Growth and Canopy USA and (ii) tax receivable bonus plans dated November 14, 2018 and subsequently amended (the "Tax Receivable Bonus Plans") between the Company and certain directors, officers, consultants of the Company, Canopy Growth and Canopy USA (together the "Tax Receivable Recipients"). Under the Tax Receivable Agreement and the Tax Receivable Bonus Plans, the Company is required to make cash payments to the Tax Receivable Recipients equal to 85% of the tax benefits, if any, that the Company actually realizes, or in certain circumstances is deemed to realize, as a result of (i) the increases in its share of the tax basis of assets of HSCP resulting from any redemptions or exchanges of Units from the HSCP Members, and (ii) certain other tax benefits related to the Company making payments under the Tax Receivable Agreement and the Tax Receivable Bonus Plan.

Surety bonds

The Company has indemnification obligations with respect to surety bonds primarily used as security against non-performance in the amount of \$5,000 as of March 31, 2023, for which no liabilities are recorded on the Unaudited Condensed Consolidated Statements of Financial Position.

The Company is subject to other capital commitments and similar obligations. As of March 31, 2023, such amounts were not material.

Contingencies

The Company's operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company's applicable subsidiaries ceasing operations. While management of the Company believes that the Company's subsidiaries are in compliance with applicable local and state regulations as of March 31, 2023, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company's subsidiaries may be subject to regulatory fines, penalties, or restrictions in the future.

The Company and its subsidiaries may be, from time to time, subject to various administrative, regulatory and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated. Refer to Note 13 of the Unaudited Condensed Consolidated Financial Statements for further discussion.

Critical accounting policies and estimates

We have adopted various accounting policies to prepare the Unaudited Condensed Consolidated Financial Statements in accordance with GAAP. Certain of our accounting policies require the application of significant judgment by management in selecting the appropriate assumptions for calculating financial estimates. In our 2022 Annual Report on Form 10-K, we identified the critical accounting policies which affect our more significant estimates and assumptions used in preparing our consolidated financial statements.

As of March 31, 2023 there have been no material changes to our critical accounting policies and estimates from those previously disclosed in our 2022 Annual Report on Form 10-K for the year ended December 31, 2022.

Item 3. Quantitative and Qualitative Disclosures About Market Risk (presented in thousands, except share amounts).

The Company has exposure to certain risks, including market, credit, liquidity, asset forfeiture, banking and interest rate risk, and assesses the impact and likelihood of those risks. However, there have been no material changes in our market risk during the three months ended March 31, 2023. For additional information, refer to our 2022 Annual Report on Form 10-K for the year ended December 31, 2022.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of the Company's management, and due to the material weakness in internal controls over financial reporting described below, the Company's principal executive officer and principal financial officer have concluded that the Company's disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were not effective for the period ending March 31, 2023 to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Inherent Limitations Over Internal Controls

The Company's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. The Company's internal control over financial reporting includes those policies and procedures that: